Main Menu

Publications Highlights View all by category

Types of Publications


Journal Articles

Oza, B. Eisen, T. Frangou, E. Stewart, G.D. Bex, A. Ritchie, A.W. Kaplan, R. Smith, B. Davis, I.D. Stockler, M.R. Albiges, L. Escudier, B. Larkin, J. Joniau, S. Hancock, B. Hermann, G.G. Bellmunt, J. Parmar, M.K. Royston, P. Meade, A. (2022). External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. , Vol.40 (16), pp. 1772-1782.  show abstract

Giles, R. Maskens, D. Bick, R. Martinez, R. Packer, M. Heng, D. Larkin, J. Bex, A. Jewett, M. Jonasch, E. MacLennan, S. (2022). Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries. , Vol.37, pp. 3-6.  show abstract

Kennedy, O.J. Kicinski, M. Valpione, S. Gandini, S. Suciu, S. Blank, C.U. Long, G.V. Atkinson, V.G. Dalle, S. Haydon, A.M. Meshcheryakov, A. Khattak, A. Carlino, M.S. Sandhu, S. Larkin, J. Puig, S. Ascierto, P.A. Rutkowski, P. Schadendorf, D. Koornstra, R. Hernandez-Aya, L. Di Giacomo, A.M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. van Akkooi, A.C. Robert, C. Eggermont, A.M. Lorigan, P. Mandala, M. (2022). Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. , Vol.165, pp. 97-112.  show abstract

Pires da Silva, I. Ahmed, T. McQuade, J.L. Nebhan, C.A. Park, J.J. Versluis, J.M. Serra-Bellver, P. Khan, Y. Slattery, T. Oberoi, H.K. Ugurel, S. Haydu, L.E. Herbst, R. Utikal, J. Pföhler, C. Terheyden, P. Weichenthal, M. Gutzmer, R. Mohr, P. Rai, R. Smith, J.L. Scolyer, R.A. Arance, A.M. Pickering, L. Larkin, J. Lorigan, P. Blank, C.U. Schadendorf, D. Davies, M.A. Carlino, M.S. Johnson, D.B. Long, G.V. Lo, S.N. Menzies, A.M. (2022). Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. J clin oncol, Vol.40 (10), pp. 1068-1080.  show abstract

Schmitt, A.M. Dumas, L. Larkin, J. (2022). Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. Expert rev anticancer ther, Vol.22 (1), pp. 17-25.  show abstract

Shum, B. Larkin, J. Turajlic, S. (2022). Predictive biomarkers for response to immune checkpoint inhibition. Seminars in cancer biology, Vol.79, pp. 4-17.

Homicsko, K. Dummer, R. Hoeller, C. Wolchok, J.D. Hodi, F.S. Larkin, J. Ascierto, P.A. Atkinson, V. Robert, C. Postow, M.A. Re, S. Paulucci, D. Dobler, D. Michielin, O. (2022). Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. , Vol.14 (9), p. 2300.  show abstract

Rini, B.I. Moslehi, J.J. Bonaca, M. Schmidinger, M. Albiges, L. Choueiri, T.K. Motzer, R.J. Atkins, M.B. Haanen, J. Mariani, M. Wang, J. Hariharan, S. Larkin, J. (2022). Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. , Vol.40 (17), pp. 1929-1938.  show abstract

Larkin, J. Weber, J. Del Vecchio, M. Gogas, H. Arance, A.M. Dalle, S. Cowey, C.L. Schenker, M. Grob, J.-. Chiarion-Sileni, V. Márquez-Rodas, I. Butler, M.O. Di Giacomo, A.M. Middleton, M.R. De la Cruz-Merino, L. Arenberger, P. Atkinson, V. Hill, A. Fecher, L.A. Millward, M. Khushalani, N.I. Queirolo, P. Long, G.V. Lobo, M. Askelson, M. Ascierto, P.A. Mandalá, M. (2022). Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. , Vol.173, pp. 285-296.  show abstract

Bilen, M.A. Rini, B.I. Voss, M.H. Larkin, J. Haanen, J.B. Albiges, L. Pagliaro, L.C. Voog, E.G. Lam, E.T. Kislov, N. McGregor, B.A. Lalani, A.-. Huang, B. di Pietro, A. Krulewicz, S. Robbins, P.B. Choueiri, T.K. (2022). Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. , Vol.28 (4), pp. 738-747.  show abstract

Yngvadottir, B. Andreou, A. Bassaganyas, L. Larionov, A. Cornish, A.J. Chubb, D. Saunders, C.N. Smith, P. Zhang, H. Cole, Y. Consortium, G.E. Larkin, J. Browning, L. Turajlic, S. Litchfield, K. Houlston, R.S. Maher, E.R. (2022). Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases. , , p. ddac089.  show abstract

Lee, C.-. Motzer, R.J. Glen, H. Michaelson, M.D. Larkin, J. Minoshima, Y. Kanekiyo, M. Ikezawa, H. Sachdev, P. Dutcus, C.E. Funahashi, Y. Voss, M.H. (2021). Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. British journal of cancer, Vol.124 (1), pp. 237-246.  show abstract

Regan, M.M. Mantia, C.M. Werner, L. Tarhini, A.A. Larkin, J. Stephen Hodi, F. Wolchok, J. Postow, M.A. Stwalley, B. Moshyk, A. Ritchings, C. Re, S. van Dijck, W. McDermott, D.F. Atkins, M.B. (2021). Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. , Vol.9 (11), p. e003743.  show abstract

Hodi, F.S. Wolchok, J.D. Schadendorf, D. Larkin, J. Long, G.V. Qian, X. Saci, A. Young, T.C. Srinivasan, S. Chang, H. Tang, H. Wind-Rotolo, M. Rizzo, J.I. Jackson, D.G. Ascierto, P.A. (2021). TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. , Vol.9 (10), pp. 1202-1213.  show abstract

Ascierto, P.A. Dréno, B. Larkin, J. Ribas, A. Liszkay, G. Maio, M. Mandalà, M. Demidov, L. Stroyakovskiy, D. Thomas, L. de la Cruz-Merino, L. Atkinson, V. Dutriaux, C. Garbe, C. Hsu, J. Jones, S. Li, H. McKenna, E. Voulgari, A. McArthur, G.A. (2021). 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. , Vol.27 (19), pp. 5225-5235.  show abstract

Mandala, M. Larkin, J. Ascierto, P.A. Del Vecchio, M. Gogas, H. Cowey, C.L. Arance, A. Dalle, S. Schenker, M. Grob, J.-. Chiarion-Sileni, V. Marquez-Rodas, I. Butler, M.O. Di Giacomo, A.M. Lutzky, J. De La Cruz-Merino, L. Atkinson, V. Arenberger, P. Hill, A. Fecher, L. Millward, M. Khushalani, N.I. de Pril, V. Lobo, M. Weber, J. (2021). Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , Vol.9 (8), p. e003188.  show abstract

Kostine, M. Finckh, A. Bingham, C.O. Visser, K. Leipe, J. Schulze-Koops, H. Choy, E.H. Benesova, K. Radstake, T.R. Cope, A.P. Lambotte, O. Gottenberg, J.-. Allenbach, Y. Visser, M. Rusthoven, C. Thomasen, L. Jamal, S. Marabelle, A. Larkin, J. Haanen, J.B. Calabrese, L.H. Mariette, X. Schaeverbeke, T. (2021). EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. , Vol.80 (1), pp. 36-48.  show abstract

Ferguson, L. Ho, B. Weir, J. Francis, N. West, K. Rathbone, B. Larkin, J. Heelan, K. (2021). Extensive mucocutaneous, oesophageal and otic lichen planus secondary to nivolumab therapy. , Vol.1 (1), p. e8.  show abstract

Saturno, G. Lopes, F. Niculescu-Duvaz, I. Niculescu-Duvaz, D. Zambon, A. Davies, L. Johnson, L. Preece, N. Lee, R. Viros, A. Holovanchuk, D. Pedersen, M. McLeary, R. Lorigan, P. Dhomen, N. Fisher, C. Banerji, U. Dean, E. Krebs, M.G. Gore, M. Larkin, J. Marais, R. Springer, C. (2021). The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers. Annals of oncology : official journal of the european society for medical oncology, Vol.32 (2), pp. 269-278.  show abstract

Edwards, C.L. Comito, F. Agraso Busto, S. Harland, C. Turajlic, S. Larkin, J. Heelan, K. Fearfield, L. (2021). Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review The experience of a single large specialist institution. Clinical and experimental dermatology, Vol.46 (2), pp. 338-341.

Meric-Bernstam, F. Larkin, J. Tabernero, J. Bonini, C. (2021). Enhancing anti-tumour efficacy with immunotherapy combinations. The lancet, Vol.397 (10278), pp. 1010-1022.

Gogas, H. Dréno, B. Larkin, J. Demidov, L. Stroyakovskiy, D. Eroglu, Z. Francesco Ferrucci, P. Pigozzo, J. Rutkowski, P. Mackiewicz, J. Rooney, I. Voulgari, A. Troutman, S. Pitcher, B. Guo, Y. Yan, Y. Castro, M. Mulla, S. Flaherty, K. Arance, A. (2021). Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Annals of oncology, Vol.32 (3), pp. 384-394.

Lidington, E. Vlooswijk, C. Stallard, K. Travis, E. Younger, E. Edwards, P. Nandhabalan, M. Hunter, N. Sarpal, N. Flett, D. Din, A. Starling, N. Larkin, J. Stanway, S. Nobbenhuis, M. Banerjee, S. Szucs, Z. Darlington, A.-. Gonzalez, M. Sirohi, B. van der Graaf, W.T. Husson, O. (2021). 'This is not part of my life plan': A qualitative study on the psychosocial experiences and practical challenges in young adults with cancer age 25 to 39 years at diagnosis. European journal of cancer care, , pp. e13458-?.  show abstract

Litchfield, K. Reading, J.L. Puttick, C. Thakkar, K. Abbosh, C. Bentham, R. Watkins, T.B. Rosenthal, R. Biswas, D. Rowan, A. Lim, E. Al Bakir, M. Turati, V. Guerra-Assunção, J.A. Conde, L. Furness, A.J. Saini, S.K. Hadrup, S.R. Herrero, J. Lee, S.-. Van Loo, P. Enver, T. Larkin, J. Hellmann, M.D. Turajlic, S. Quezada, S.A. McGranahan, N. Swanton, C. (2021). Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. , Vol.184 (3), pp. 596-614.e14.  show abstract

Olofsson Bagge, R. Ny, L. Ascierto, P.A. Hodi, F.S. Larkin, J. Robert, C. Schachter, J. Weber, J.S. Long, G.V. van Akkooi, A.C. (2021). The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma research, Vol.31 (2), pp. 181-185.

Ho, B. Larkin, J. Heelan, K. (2021). Checkpoint Inhibitor-associated Cutaneous Small Vessel Vasculitis: A Review of the Literature. Journal of immunotherapy, Vol.44 (3), pp. 118-121.

Bottomley, A. Coens, C. Mierzynska, J. Blank, C.U. Mandalà, M. Long, G.V. Atkinson, V.G. Dalle, S. Haydon, A.M. Meshcheryakov, A. Khattak, A. Carlino, M.S. Sandhu, S. Puig, S. Ascierto, P.A. Larkin, J. Lorigan, P.C. Rutkowski, P. Schadendorf, D. Koornstra, R. Hernandez-Aya, L. Di Giacomo, A.M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. van Akkooi, A.C. Krepler, C. Ibrahim, N. Marreaud, S. Kicinski, M. Suciu, S. Robert, C. Eggermont, A.M. Lesimple, T. Maio, M. Linette, G. Mortier, L. Svane, I.M. Schachter, J. Brown, M. Hersey, P. Barrow, C. Kudchadkar, R. Dutriaux, C. Song, X. Quaglino, P. Queirolo, P. Meier, F. Stroyakovskiy, D. Guillot, B. Romero, P.L. Bastholt, L. Garbe, C. Grange, F. Mohr, P. Algazi, A. Bechter, O. Hernberg, M. Loquai, C. Meiss, F. Chiarion Sileni, V. Bar-Sela, G. Fitzharris, B. Saiag, P. Arnault, J.-. Simon, J.-. Stephens, R. Baurain, J.-. Lebbe, C. Combemale, P. Dummer, R. Hauschild, A. Parente, P. Yamazaki, N. Milhem, M. Leccia, M.-. Geoffrois, L. Kretschmer, L. Dunwoodie, E. Walker, J. Lotem, M. Hendler, D. Mackiewicz, A. Sekulovic, L. Dzienis, M. Hospers, G.A. Siano, M. Hassel, J. Corrie, P. Passos, M.-. Levin, M. Hoeller, C. Machet, L. Hallmeyer, S. Waterston, A. Descamps, V. Kiecker, F. Aarts, M. Schmidt, H. Raimundo, A. Nyakas, M. Lacour, J.-. Berking, C. Ferrucci, P.F. Jameson, M. Kim, K. Yokota, K. Kerger, J. Aubin, F. Groenewegen, G. Kapiteijn, H. Boehncke, W.-. Utikal, J. Casasola, R. Marshall, E. Ferraresi, V. Richtig, E. Matkovic, S. Inozume, T. Crook, T. McNeil, C. Kiyohara, Y. Avril, M.-. Hein, R. Terheyden, P. Nathan, P. Aoi, J. Skytta, T. Jouary, T. Takenouchi, T. Straume, O. Martins, C. Mukhametshina, G. (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The lancet oncology, Vol.22 (5), pp. 655-664.

Eggermont, A.M. Blank, C.U. Mandalà, M. Long, G.V. Atkinson, V.G. Dalle, S. Haydon, A.M. Meshcheryakov, A. Khattak, A. Carlino, M.S. Sandhu, S. Larkin, J. Puig, S. Ascierto, P.A. Rutkowski, P. Schadendorf, D. Koornstra, R. Hernandez-Aya, L. Di Giacomo, A.M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. Lorigan, P.C. van Akkooi, A.C. Krepler, C. Ibrahim, N. Marreaud, S. Kicinski, M. Suciu, S. Robert, C. Menzies, A. Lesimple, T. Maio, M. Linette, G. Brown, M. Hersey, P. Svane, I.M. Mortier, L. Schachter, J. Barrow, C. Kudchadkar, R. Song, X. Dutriaux, C. Quaglino, P. Meier, F. Queirolo, P. Stroyakovskiy, D. Bastholt, L. Guillot, B. Garbe, C. Ortiz Romero, P.L. Grange, F. Mohr, P. Algazi, A. Bechter, O. Hernberg, M. Arnault, J.-. Saiag, P. Loquai, C. Meiss, F. Simon, J.-. Bar-Sela, G. Chiarion Sileni, V. Fitzharris, B. McCrystal, M. Parente, P. Baurain, J.-. Combemale, P. Lebbe, C. Hauschild, A. Yamazaki, N. Dummer, R. Milhem, M. Dzienis, M. Walker, J. Geoffrois, L. Leccia, M.-. Kretschmer, L. Hendler, D. Lotem, M. Mackiewicz, A. Sekulovic, L. Dunwoodie, E. Hoeller, C. Machet, L. Hassel, J. Hospers, G.A. Passos, M.-. Levin, M. Fehr, M. Corrie, P. Waterston, A. Hallmeyer, S. Schmidt, H. Descamps, V. Lacour, J.-. Berking, C. Kiecker, F. Ferrucci, P.F. Yokota, K. Aarts, M. Jameson, M. Winge-Main, A.K. Ferreira, P. Kim, K. McNeil, C. Hofmann-Wellenhof, R. Kerger, J. Aubin, F. Utikal, J. Ferraresi, V. Inozume, T. Kiyohara, Y. Groenewegen, G. Kapiteijn, H. Matkovic, S. Boehncke, W.-. Casasola, R. Crook, T. Marshall, E. Skytta, T. Avril, M.-. Jouary, T. Hein, R. Terheyden, P. Aoi, J. Takenouchi, T. Straume, O. Martins, C. Mukhametshina, G. Nathan, P. (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. The lancet oncology, Vol.22 (5), pp. 643-654.

Kohoutova, D. Worku, D. Aziz, H. Teare, J. Weir, J. Larkin, J. (2021). Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options. , Vol.10 (2), p. 327.  show abstract

Tarhini, A.A. Toor, K. Chan, K. McDermott, D.F. Mohr, P. Larkin, J. Hodi, F.S. Lee, C.-. Rizzo, J.I. Johnson, H. Moshyk, A. Rao, S. Kotapati, S. Atkins, M.B. (2021). A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆. , Vol.6 (2), p. 100050.  show abstract

Percik, R. Larkin, J. Morganstein, D.L. (2021). Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis. The lancet oncology, Vol.22 (7), pp. 905-907.

Rzeniewicz, K. Larkin, J. Menzies, A.M. Turajlic, S. (2021). Immunotherapy use outside clinical trial populations: never say never?. Annals of oncology, Vol.32 (7), pp. 866-880.

Dearden, H. Au, L. Wang, D.Y. Zimmer, L. Eroglu, Z. Smith, J.L. Cuvietto, M. Khoo, C. Atkinson, V. Lo, S. Long, G.V. Sandhu, S. Ascierto, P.A. Carlino, M.S. Johnson, D.B. Larkin, J. Menzies, A.M. (2021). Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European journal of cancer, Vol.153, pp. 168-178.

Hepner, A. Atkinson, V.G. Larkin, J. Burrell, R.A. Carlino, M.S. Johnson, D.B. Zimmer, L. Tsai, K.K. Klein, O. Lo, S.N. Haydon, A. Bhave, P. Lyle, M. Pallan, L. Pires da Silva, I. Gerard, C. Michielin, O. Long, G.V. Menzies, A.M. (2021). Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapy. European journal of cancer, Vol.153, pp. 213-222.

Uthayakumar, A.K. Rudd, E. Noy, M. Weir, J. Larkin, J. Fearfield, L. (2021). Severe progressive scarring pembrolizumab‐induced lichen planopilaris in a patient with metastatic melanoma. Australasian journal of dermatology, Vol.62 (3), pp. 403-406.

Carlino, M.S. Larkin, J. Long, G.V. (2021). Immune checkpoint inhibitors in melanoma. The lancet, Vol.398 (10304), pp. 1002-1014.

Mendis, S. Ealing, J. Larkin, J. Turajlic, S. Carr, A. Bronstein, A. Kaski, D. (2021). Isolated imbalance due to bilateral vestibular failure following immune checkpoint inhibitor administration: two cases. European journal of cancer, Vol.156, pp. 187-189.

Sarnaik, A.A. Hamid, O. Khushalani, N.I. Lewis, K.D. Medina, T. Kluger, H.M. Thomas, S.S. Domingo-Musibay, E. Pavlick, A.C. Whitman, E.D. Martin-Algarra, S. Corrie, P. Curti, B.D. Oláh, J. Lutzky, J. Weber, J.S. Larkin, J.M. Shi, W. Takamura, T. Jagasia, M. Qin, H. Wu, X. Chartier, C. Graf Finckenstein, F. Fardis, M. Kirkwood, J.M. Chesney, J.A. (2021). Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. Journal of clinical oncology : official journal of the american society of clinical oncology, , pp. JCO2100612-?.  show abstract

Nogueira, E. Menon, A. Dede, A. Mitra, I. Brock, C. Larkin, J. Morganstein, D. (2021). Pituitary enlargement following ipilimumab without long term endocrine dysfunction. Current problems in cancer, Vol.45 (6), pp. 100710-100710.

Aeppli, S. Schmaus, M. Eisen, T. Escudier, B. Grünwald, V. Larkin, J. McDermott, D. Oldenburg, J. Porta, C. Rini, B.I. Schmidinger, M. Sternberg, C.N. Rothermundt, C. Putora, P.M. (2021). First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. , Vol.6 (1), p. 100030.  show abstract

Oza, B. Frangou, E. Smith, B. Bryant, H. Kaplan, R. Choodari-Oskooei, B. Powles, T. Stewart, G.D. Albiges, L. Bex, A. Choueiri, T.K. Davis, I.D. Eisen, T. Fielding, A. Harrison, D. McWhirter, A. Mulhere, S. Nathan, P. Rini, B. Ritchie, A. Scovell, S. Shakeshaft, C. Stockler, M.R. Thorogood, N. Parmar, M.K. Larkin, J. Meade, A. (2021). RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. , Vol.108, p. 106482.  show abstract

Meade, A. Oza, B. Frangou, E. Smith, B. Bryant, H. Kaplan, R. Choodari-Oskooei, B. Powles, T. Stewart, G.D. Albiges, L. Bex, A. Choueiri, T.K. Davis, I.D. Eisen, T. Fielding, A. Harrison, D.J. McWhirter, A. Mulhere, S. Nathan, P. Rini, B. Ritchie, A. Scovell, S. Shakeshaft, C. Stockler, M.R. Thorogood, N. Larkin, J. Parmar, M.K. (2021). RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. , Vol.108, p. 106481.  show abstract

Zhao, Y. Fu, X. Lopez, J.I. Rowan, A. Au, L. Fendler, A. Hazell, S. Xu, H. Horswell, S. Shepherd, S.T. Spain, L. Byrne, F. Stamp, G. O'Brien, T. Nicol, D. Augustine, M. Chandra, A. Rudman, S. Toncheva, A. Pickering, L. Sahai, E. Larkin, J. Bates, P.A. Swanton, C. Turajlic, S. TRACERx Renal Consortium, Litchfield, K. (2021). Selection of metastasis competent subclones in the tumour interior. , Vol.5 (7), pp. 1033-1045.  show abstract

Eggermont, A.M. Meshcheryakov, A. Atkinson, V. Blank, C.U. Mandala, M. Long, G.V. Barrow, C. Di Giacomo, A.M. Fisher, R. Sandhu, S. Kudchadkar, R. Ortiz Romero, P.L. Svane, I.M. Larkin, J. Puig, S. Hersey, P. Quaglino, P. Queirolo, P. Stroyakovskiy, D. Bastholt, L. Mohr, P. Hernberg, M. Chiarion-Sileni, V. Strother, M. Hauschild, A. Yamazaki, N. van Akkooi, A.C. Lorigan, P. Krepler, C. Ibrahim, N. Marreaud, S. Kicinski, M. Suciu, S. Robert, C. (2021). Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. , Vol.158, pp. 156-168.  show abstract

McDermott, D.F. Lee, J.-. Bjarnason, G.A. Larkin, J.M. Gafanov, R.A. Kochenderfer, M.D. Jensen, N.V. Donskov, F. Malik, J. Poprach, A. Tykodi, S.S. Alonso-Gordoa, T. Cho, D.C. Geertsen, P.F. Climent Duran, M.A. DiSimone, C. Silverman, R.K. Perini, R.F. Schloss, C. Atkins, M.B. (2021). Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. , Vol.39 (9), pp. 1020-1028.  show abstract

Choueiri, T.K. Larkin, J. Pal, S. Motzer, R.J. Rini, B.I. Venugopal, B. Alekseev, B. Miyake, H. Gravis, G. Bilen, M.A. Hariharan, S. Chudnovsky, A. Ching, K.A. Mu, X.J. Mariani, M. Robbins, P.B. Huang, B. di Pietro, A. Albiges, L. (2021). Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. , Vol.6 (3), p. 100101.  show abstract

Au, L. Fendler, A. Shepherd, S.T. Rzeniewicz, K. Cerrone, M. Byrne, F. Carlyle, E. Edmonds, K. Del Rosario, L. Shon, J. Haynes, W.A. Ward, B. Shum, B. Gordon, W. Gerard, C.L. Xie, W. Joharatnam-Hogan, N. Young, K. Pickering, L. Furness, A.J. Larkin, J. Harvey, R. Kassiotis, G. Gandhi, S. Crick COVID-19 Consortium, Swanton, C. Fribbens, C. Wilkinson, K.A. Wilkinson, R.J. Lau, D.K. Banerjee, S. Starling, N. Chau, I. CAPTURE Consortium, Turajlic, S. (2021). Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. Nature medicine, .  show abstract

Fendler, A. Shepherd, S.T. Au, L. Wilkinson, K.A. Wu, M. Byrne, F. Cerrone, M. Schmitt, A.M. Joharatnam-Hogan, N. Shum, B. Tippu, Z. Rzeniewicz, K. Boos, L.A. Harvey, R. Carlyle, E. Edmonds, K. Del Rosario, L. Sarker, S. Lingard, K. Mangwende, M. Holt, L. Ahmod, H. Korteweg, J. Foley, T. Bazin, J. Gordon, W. Barber, T. Emslie-Henry, A. Xie, W. Gerard, C.L. Deng, D. Wall, E.C. Agua-Doce, A. Namjou, S. Caidan, S. Gavrielides, M. MacRae, J. Kelly, G. Peat, K. Kelly, D. Murra, A. Kelly, K. O'Flaherty, M. Dowdie, L. Ash, N. Gronthoud, F. Shea, R.L. Gardner, G. Murray, D. Kinnaird, F. Cui, W. Pascual, J. Rodney, S. Mencel, J. Curtis, O. Stephenson, C. Robinson, A. Oza, B. Farag, S. Leslie, I. Rogiers, A. Iyengar, S. Ethell, M. Messiou, C. Cunningham, D. Chau, I. Starling, N. Turner, N. Welsh, L. van As, N. Jones, R.L. Droney, J. Banerjee, S. Tatham, K.C. O'Brien, M. Harrington, K. Bhide, S. Okines, A. Reid, A. Young, K. Furness, A.J. Pickering, L. Swanton, C. Gandhi, S. Gamblin, S. Bauer, D.L. Kassiotis, G. Kumar, S. Yousaf, N. Jhanji, S. Nicholson, E. Howell, M. Walker, S. Wilkinson, R.J. Larkin, J. Turajlic, S. (2021). Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature cancer, , pp. ?-? (31).

Scherrer, E. Rau, R. Lorenzi, M. Shui, I. Townson, S. Larkin, J. (2021). Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma. , Vol.17 (20), pp. 2683-2692.  show abstract

Piperno-Neumann, S. Larkin, J. Carvajal, R.D. Luke, J.J. Schwartz, G.K. Hodi, F.S. Sablin, M.-. Shoushtari, A.N. Szpakowski, S. Chowdhury, N.R. Brannon, A.R. Ramkumar, T. de Koning, L. Derti, A. Emery, C. Yerramilli-Rao, P. Kapiteijn, E. (2020). Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. Molecular cancer therapeutics, Vol.19 (4), pp. 1031-1039.  show abstract

Eggermont, A.M. Kicinski, M. Blank, C.U. Mandala, M. Long, G.V. Atkinson, V. Dalle, S. Haydon, A. Khattak, A. Carlino, M.S. Sandhu, S. Larkin, J. Puig, S. Ascierto, P.A. Rutkowski, P. Schadendorf, D. Koornstra, R. Hernandez-Aya, L. Di Giacomo, A.M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. Lorigan, P.C. Krepler, C. Ibrahim, N. Marreaud, S. van Akkooi, A. Robert, C. Suciu, S. (2020). Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. , Vol.6 (4), pp. 519-527.  show abstract

Peach, H. Board, R. Cook, M. Corrie, P. Ellis, S. Geh, J. King, P. Laitung, G. Larkin, J. Marsden, J. Middleton, M. Moncrieff, M. Nathan, P. Powell, B. Pritchard-Jones, R. Rodwell, S. Steven, N. Lorigan, P. (2020). Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement. Journal of plastic, reconstructive & aesthetic surgery, Vol.73 (1), pp. 36-42.

Haanen, J. Ernstoff, M. Wang, Y. Menzies, A. Puzanov, I. Grivas, P. Larkin, J. Peters, S. Thompson, J. Obeid, M. (2020). Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. , Vol.8 (1), p. e000604.  show abstract

Powell, N. Ibraheim, H. Raine, T. Speight, R.A. Papa, S. Brain, O. Green, M. Samaan, M.A. Spain, L. Yousaf, N. Hunter, N. Eldridge, L. Pavlidis, P. Irving, P. Hayee, B. Turajlic, S. Larkin, J. Lindsay, J.O. Gore, M. (2020). British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. , Vol.5 (7), pp. 679-697.  show abstract

Schmidinger, M. Porta, C. Oudard, S. Denechere, G. Brault, Y. Serfass, L. Costa, N. Larkin, J. (2020). Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score. , Vol.18 (5), pp. e588-e597.  show abstract

Aeppli, S. Eboulet, E.I. Eisen, T. Escudier, B. Fischer, S. Larkin, J. Gruenwald, V. McDermott, D. Oldenburg, J. Omlin, A. Porta, C. Rini, B. Schmidinger, M. Sternberg, C. Rothermundt, C. (2020). Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. , Vol.5 (Suppl 3), p. e000852.  show abstract

Favara, D.M. Spain, L. Au, L. Clark, J. Daniels, E. Diem, S. Chauhan, D. Turajlic, S. Powell, N. Larkin, J.M. Yousaf, N. (2020). Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. , Vol.5 (4), p. e000585.  show abstract

Eisen, T. Frangou, E. Oza, B. Ritchie, A.W. Smith, B. Kaplan, R. Davis, I.D. Stockler, M.R. Albiges, L. Escudier, B. Larkin, J. Bex, A. Joniau, S. Hancock, B. Hermann, G.G. Bellmunt, J. Hodgkinson, E. Stewart, G.D. Barber, J. Brown, J. McMenemin, R. Nathan, P. Pickering, L.M. Parmar, M.K. Meade, A. (2020). Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. J clin oncol, Vol.38 (34), pp. 4064-4075.  show abstract

Boos, L.A. Leslie, I. Larkin, J. (2020). Metastatic melanoma: therapeutic agents in preclinical and early clinical development. Expert opinion on investigational drugs, Vol.29 (7), pp. 739-753.

O'Reilly, A. Hughes, P. Mann, J. Lai, Z. Teh, J.J. Mclean, E. Edmonds, K. Lingard, K. Chauhan, D. Lynch, J. Au, L. Ludlow, A. Pattison, N. Wiseman, T. Turajlic, S. Gore, M. Larkin, J. Husson, O. (2020). An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Supportive care in cancer : official journal of the multinational association of supportive care in cancer, Vol.28 (2), pp. 561-570.  show abstract

Ascierto, P.A. Ribas, A. Larkin, J. McArthur, G.A. Lewis, K.D. Hauschild, A. Flaherty, K.T. McKenna, E. Zhu, Q. Mun, Y. Dréno, B. (2020). Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials. Journal of translational medicine, Vol.18 (1), pp. 294-?.  show abstract

Leslie, I. Boos, L.A. Larkin, J. Pickering, L. (2020). Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. Expert review of anticancer therapy, Vol.20 (5), pp. 343-354.

Dummer, R. Brase, J.C. Garrett, J. Campbell, C.D. Gasal, E. Squires, M. Gusenleitner, D. Santinami, M. Atkinson, V. Mandalà, M. Chiarion-Sileni, V. Flaherty, K. Larkin, J. Robert, C. Kefford, R. Kirkwood, J.M. Hauschild, A. Schadendorf, D. Long, G.V. (2020). Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. The lancet oncology, Vol.21 (3), pp. 358-372.

Litchfield, K. Stanislaw, S. Spain, L. Gallegos, L.L. Rowan, A. Schnidrig, D. Rosenbaum, H. Harle, A. Au, L. Hill, S.M. Tippu, Z. Thomas, J. Thompson, L. Xu, H. Horswell, S. Barhoumi, A. Jones, C. Leith, K.F. Burgess, D.L. Watkins, T.B. Lim, E. Birkbak, N.J. Lamy, P. Nordentoft, I. Dyrskjøt, L. Pickering, L. Hazell, S. Jamal-Hanjani, M. PEACE Consortium, Larkin, J. Swanton, C. Alexander, N.R. Turajlic, S. (2020). Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. , Vol.31 (5), p. 107550.  show abstract

Ugurel, S. Röhmel, J. Ascierto, P.A. Becker, J.C. Flaherty, K.T. Grob, J.J. Hauschild, A. Larkin, J. Livingstone, E. Long, G.V. Lorigan, P. McArthur, G.A. Ribas, A. Robert, C. Zimmer, L. Schadendorf, D. Garbe, C. (2020). Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. European journal of cancer, Vol.130, pp. 126-138.

Haanen, J. Ernstoff, M.S. Wang, Y. Menzies, A.M. Puzanov, I. Grivas, P. Larkin, J. Peters, S. Thompson, J.A. Obeid, M. (2020). Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Annals of oncology, Vol.31 (6), pp. 724-744.

Maio, M. Hamid, O. Larkin, J. Covre, A. Altomonte, M. Calabrò, L. Vardhana, S.A. Robert, C. Ibrahim, R. Anichini, A. Wolchok, J.D. Giacomo, A.M. (2020). Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. Clinical cancer research : an official journal of the american association for cancer research, Vol.26 (16), pp. 4201-4205.  show abstract

Choueiri, T.K. Motzer, R.J. Rini, B.I. Haanen, J. Campbell, M.T. Venugopal, B. Kollmannsberger, C. Gravis-Mescam, G. Uemura, M. Lee, J.L. Grimm, M.-. Gurney, H. Schmidinger, M. Larkin, J. Atkins, M.B. Pal, S.K. Wang, J. Mariani, M. Krishnaswami, S. Cislo, P. Chudnovsky, A. Fowst, C. Huang, B. di Pietro, A. Albiges, L. (2020). Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Annals of oncology : official journal of the european society for medical oncology, Vol.31 (8), pp. 1030-1039.  show abstract

Owen, C.N. Shoushtari, A.N. Chauhan, D. Palmieri, D.J. Lee, B. Rohaan, M.W. Mangana, J. Atkinson, V. Zaman, F. Young, A. Hoeller, C. Hersey, P. Dummer, R. Khattak, M.A. Millward, M. Patel, S.P. Haydon, A. Johnson, D.B. Lo, S. Blank, C.U. Sandhu, S. Carlino, M.S. Larkin, J.M. Menzies, A.M. Long, G.V. (2020). Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆. Annals of oncology, Vol.31 (8), pp. 1075-1082.

Sud, A. Torr, B. Jones, M.E. Broggio, J. Scott, S. Loveday, C. Garrett, A. Gronthoud, F. Nicol, D.L. Jhanji, S. Boyce, S.A. Williams, M. Riboli, E. Muller, D.C. Kipps, E. Larkin, J. Navani, N. Swanton, C. Lyratzopoulos, G. McFerran, E. Lawler, M. Houlston, R. Turnbull, C. (2020). Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. The lancet. oncology, Vol.21 (8), pp. 1035-1044.  show abstract

Sud, A. Jones, M.E. Broggio, J. Loveday, C. Torr, B. Garrett, A. Nicol, D.L. Jhanji, S. Boyce, S.A. Gronthoud, F. Ward, P. Handy, J.M. Yousaf, N. Larkin, J. Suh, Y.-. Scott, S. Pharoah, P.D. Swanton, C. Abbosh, C. Williams, M. Lyratzopoulos, G. Houlston, R. Turnbull, C. (2020). Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Annals of oncology : official journal of the european society for medical oncology, Vol.31 (8), pp. 1065-1074.  show abstract

Hall, P.E. Shepherd, S.T. Brown, J. Larkin, J. Jones, R. Ralph, C. Hawkins, R. Chowdhury, S. Boleti, E. Bahl, A. Fife, K. Webb, A. Crabb, S.J. Geldart, T. Hill, R. Dunlop, J. McLaren, D. Ackerman, C. Wimalasingham, A. Beltran, L. Nathan, P. Powles, T. (2020). Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. European urology focus, Vol.6 (5), pp. 999-1005.

Khushalani, N.I. Diab, A. Ascierto, P.A. Larkin, J. Sandhu, S. Sznol, M. Koon, H.B. Jarkowski, A. Zhou, M. Statkevich, P. Geese, W.J. Long, G.V. (2020). Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future oncology, Vol.16 (28), pp. 2165-2175.  show abstract

Comito, F. Leslie, I. Boos, L. Furness, A. Pickering, L. Turajlic, S. Larkin, J. (2020). Oligoprogression After Checkpoint Inhibition in Metastatic Melanoma Treated With Locoregional Therapy: A Single-center Retrospective Analysis. Journal of immunotherapy, Vol.43 (8), pp. 250-255.

Motzer, R.J. Robbins, P.B. Powles, T. Albiges, L. Haanen, J.B. Larkin, J. Mu, X.J. Ching, K.A. Uemura, M. Pal, S.K. Alekseev, B. Gravis, G. Campbell, M.T. Penkov, K. Lee, J.L. Hariharan, S. Wang, X. Zhang, W. Wang, J. Chudnovsky, A. di Pietro, A. Donahue, A.C. Choueiri, T.K. (2020). Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nature medicine, Vol.26 (11), pp. 1733-1741.

Ascierto, P.A. Del Vecchio, M. Mandalá, M. Gogas, H. Arance, A.M. Dalle, S. Cowey, C.L. Schenker, M. Grob, J.-. Chiarion-Sileni, V. Márquez-Rodas, I. Butler, M.O. Maio, M. Middleton, M.R. de la Cruz-Merino, L. Arenberger, P. Atkinson, V. Hill, A. Fecher, L.A. Millward, M. Khushalani, N.I. Queirolo, P. Lobo, M. de Pril, V. Loffredo, J. Larkin, J. Weber, J. (2020). Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. The lancet oncology, Vol.21 (11), pp. 1465-1477.

de Boer, R.A. Hulot, J.-. Tocchetti, C.G. Aboumsallem, J.P. Ameri, P. Anker, S.D. Bauersachs, J. Bertero, E. Coats, A.J. Čelutkienė, J. Chioncel, O. Dodion, P. Eschenhagen, T. Farmakis, D. Bayes-Genis, A. Jäger, D. Jankowska, E.A. Kitsis, R.N. Konety, S.H. Larkin, J. Lehmann, L. Lenihan, D.J. Maack, C. Moslehi, J.J. Müller, O.J. Nowak-Sliwinska, P. Piepoli, M.F. Ponikowski, P. Pudil, R. Rainer, P.P. Ruschitzka, F. Sawyer, D. Seferovic, P.M. Suter, T. Thum, T. van der Meer, P. Van Laake, L.W. von Haehling, S. Heymans, S. Lyon, A.R. Backs, J. (2020). Common mechanistic pathways in cancer and heart failure A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). , Vol.22 (12), pp. 2272-2289.  show abstract

Motzer, R.J. Escudier, B. George, S. Hammers, H.J. Srinivas, S. Tykodi, S.S. Sosman, J.A. Plimack, E.R. Procopio, G. McDermott, D.F. Castellano, D. Choueiri, T.K. Donskov, F. Gurney, H. Oudard, S. Richardet, M. Peltola, K. Alva, A.S. Carducci, M. Wagstaff, J. Chevreau, C. Fukasawa, S. Tomita, Y. Gauler, T.C. Kollmannsberger, C.K. Schutz, F.A. Larkin, J. Cella, D. McHenry, M.B. Saggi, S.S. Tannir, N.M. (2020). Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial. Cancer, Vol.126 (18), pp. 4156-4167.

Dummer, R. Hauschild, A. Santinami, M. Atkinson, V. Mandalà, M. Kirkwood, J.M. Chiarion Sileni, V. Larkin, J. Nyakas, M. Dutriaux, C. Haydon, A. Robert, C. Mortier, L. Schachter, J. Lesimple, T. Plummer, R. Dasgupta, K. Gasal, E. Tan, M. Long, G.V. Schadendorf, D. (2020). Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. New england journal of medicine, Vol.383 (12), pp. 1139-1148.

Eggermont, A.M. Blank, C.U. Mandala, M. Long, G.V. Atkinson, V.G. Dalle, S. Haydon, A.M. Meshcheryakov, A. Khattak, A. Carlino, M.S. Sandhu, S. Larkin, J. Puig, S. Ascierto, P.A. Rutkowski, P. Schadendorf, D. Koornstra, R. Hernandez-Aya, L. Di Giacomo, A.M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. Lorigan, P.C. van Akkooi, A.C. Krepler, C. Ibrahim, N. Marreaud, S. Kicinski, M. Suciu, S. Robert, C. (2020). Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. J clin oncol, Vol.38 (33), pp. 3925-3936.  show abstract

Siddiqui, M.S. Lai, Z.M. Spain, L. Greener, V. Turajlic, S. Larkin, J. Morganstein, D.L. (2020). Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH. , Vol.44 (1), pp. 195-203.  show abstract

Litchfield, K. Reading, J.L. Lim, E.L. Xu, H. Liu, P. Al-Bakir, M. Wong, Y.N. Rowan, A. Funt, S.A. Merghoub, T. Perkins, D. Lauss, M. Svane, I.M. Jönsson, G. Herrero, J. Larkin, J. Quezada, S.A. Hellmann, M.D. Turajlic, S. Swanton, C. (2020). Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. , Vol.11 (1), p. 3800.  show abstract

Larkin, J. Brown, M.P. Arance, A.M. Hauschild, A. Queirolo, P. Vecchio, M.D. Ascierto, P.A. Krajsová, I. Schachter, J. Neyns, B. Garbe, C. Sileni, V.C. Mandalà, M. Gogas, H. Espinosa, E. Hospers, G. Lorigan, P. Nyakas, M. Guminski, A. Liszkay, G. Rutkowski, P. Miller, W. Donica, M. Makrutzki, M. Blank, C. (2019). An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. European journal of cancer, Vol.107, pp. 175-185.

Hayes, A.J. Moskovic, E. O'Meara, K. Smith, H.G. Pope, R.J. Larkin, J. Thomas, J.M. (2019). Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate-risk cutaneous melanoma. , Vol.106 (6), pp. 729-734.  show abstract

Yan, Y. Wongchenko, M.J. Robert, C. Larkin, J. Ascierto, P.A. Dréno, B. Maio, M. Garbe, C. Chapman, P.B. Sosman, J.A. Shi, Z. Koeppen, H. Hsu, J.J. Chang, I. Caro, I. Rooney, I. McArthur, G.A. Ribas, A. (2019). Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma. Clinical cancer research, Vol.25 (11), pp. 3239-3246.  show abstract

Michaelson, M.D. Gupta, S. Agarwal, N. Szmulewitz, R. Powles, T. Pili, R. Bruce, J.Y. Vaishampayan, U. Larkin, J. Rosbrook, B. Wang, E. Murphy, D. Wang, P. Lechuga, M.J. Valota, O. Shepard, D.R. (2019). A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. The oncologist, Vol.24 (9), pp. 1151-e817.  show abstract

Lewis, K.D. Larkin, J. Ribas, A. Flaherty, K.T. McArthur, G.A. Ascierto, P.A. Dréno, B. Yan, Y. Wongchenko, M. McKenna, E. Zhu, Q. Mun, Y. Hauschild, A. (2019). Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. , Vol.121 (7), pp. 522-528.  show abstract

Spain, L. Tippu, Z. Larkin, J.M. Carr, A. Turajlic, S. (2019). How we treat neurological toxicity from immune checkpoint inhibitors. , Vol.4 (Suppl 4), p. e000540.  show abstract

Johansson, M. Carreras-Torres, R. Scelo, G. Purdue, M.P. Mariosa, D. Muller, D.C. Timpson, N.J. Haycock, P.C. Brown, K.M. Wang, Z. Ye, Y. Hofmann, J.N. Foll, M. Gaborieau, V. Machiela, M.J. Colli, L.M. Li, P. Garnier, J.-. Blanche, H. Boland, A. Burdette, L. Prokhortchouk, E. Skryabin, K.G. Yeager, M. Radojevic-Skodric, S. Ognjanovic, S. Foretova, L. Holcatova, I. Janout, V. Mates, D. Mukeriya, A. Rascu, S. Zaridze, D. Bencko, V. Cybulski, C. Fabianova, E. Jinga, V. Lissowska, J. Lubinski, J. Navratilova, M. Rudnai, P. Benhamou, S. Cancel-Tassin, G. Cussenot, O. Weiderpass, E. Ljungberg, B. Tumkur Sitaram, R. Häggström, C. Bruinsma, F. Jordan, S.J. Severi, G. Winship, I. Hveem, K. Vatten, L.J. Fletcher, T. Larsson, S.C. Wolk, A. Banks, R.E. Selby, P.J. Easton, D.F. Andreotti, G. Beane Freeman, L.E. Koutros, S. Männistö, S. Weinstein, S. Clark, P.E. Edwards, T.L. Lipworth, L. Gapstur, S.M. Stevens, V.L. Carol, H. Freedman, M.L. Pomerantz, M.M. Cho, E. Wilson, K.M. Gaziano, J.M. Sesso, H.D. Freedman, N.D. Parker, A.S. Eckel-Passow, J.E. Huang, W.-. Kahnoski, R.J. Lane, B.R. Noyes, S.L. Petillo, D. Teh, B.T. Peters, U. White, E. Anderson, G.L. Johnson, L. Luo, J. Buring, J. Lee, I.-. Chow, W.-. Moore, L.E. Eisen, T. Henrion, M. Larkin, J. Barman, P. Leibovich, B.C. Choueiri, T.K. Lathrop, G.M. Deleuze, J.-. Gunter, M. McKay, J.D. Wu, X. Houlston, R.S. Chanock, S.J. Relton, C. Richards, J.B. Martin, R.M. Davey Smith, G. Brennan, P. (2019). The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study. Plos medicine, Vol.16 (1), pp. e1002724-?.  show abstract

Robert, C. Flaherty, K. Nathan, P. Hersey, P. Garbe, C. Milhem, M. Demidov, L. Mohr, P. Hassel, J.C. Rutkowski, P. Dummer, R. Utikal, J. Kiecker, F. Larkin, J. D'Amelio, A. Mookerjee, B. Schadendorf, D. (2019). Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma. European journal of cancer, Vol.109, pp. 61-69.

Ingles Garces, A.H. Au, L. Mason, R. Thomas, J. Larkin, J. (2019). Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer. Expert opinion on investigational drugs, Vol.28 (8), pp. 695-708.

Schadendorf, D. Hauschild, A. Santinami, M. Atkinson, V. Mandalà, M. Chiarion-Sileni, V. Larkin, J. Nyakas, M. Dutriaux, C. Haydon, A. Robert, C. Mortier, L. Lesimple, T. Plummer, R. Schachter, J. Dasgupta, K. Manson, S. Koruth, R. Mookerjee, B. Kefford, R. Dummer, R. Kirkwood, J.M. Long, G.V. (2019). Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. The lancet oncology, Vol.20 (5), pp. 701-710.

Lewis, K. Hauschild, A. Larkin, J. Ribas, A. Flaherty, K.T. McArthur, G.A. Dréno, B. McKenna, E. Zhu, Q. Mun, Y. Ascierto, P.A. (2019). Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation–positive metastatic melanoma treated with vemurafenib ± cobimetinib. European journal of cancer, Vol.116, pp. 45-55.

Kreft, S. Gesierich, A. Eigentler, T. Franklin, C. Valpione, S. Ugurel, S. Utikal, J. Haferkamp, S. Blank, C. Larkin, J. Garbe, C. Schadendorf, D. Lorigan, P. Schilling, B. (2019). Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. European journal of cancer, Vol.116, pp. 207-215.

Eggermont, A.M. Blank, C.U. Mandala, M. Long, G.V. Atkinson, V.G. Dalle, S. Haydon, A. Lichinitser, M. Khattak, A. Carlino, M.S. Sandhu, S. Larkin, J. Puig, S. Ascierto, P.A. Rutkowski, P. Schadendorf, D. Koornstra, R. Hernandez-Aya, L. Di Giacomo, A.M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. Lorigan, P.C. Lupinacci, R. Krepler, C. Ibrahim, N. Kicinski, M. Marreaud, S. van Akkooi, A.C. Suciu, S. Robert, C. (2019). Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. European journal of cancer, Vol.116, pp. 148-157.

Long, G.V. Dummer, R. Hamid, O. Gajewski, T.F. Caglevic, C. Dalle, S. Arance, A. Carlino, M.S. Grob, J.-. Kim, T.M. Demidov, L. Robert, C. Larkin, J. Anderson, J.R. Maleski, J. Jones, M. Diede, S.J. Mitchell, T.C. (2019). Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. The lancet oncology, Vol.20 (8), pp. 1083-1097.

Robert, C. Ribas, A. Schachter, J. Arance, A. Grob, J.-. Mortier, L. Daud, A. Carlino, M.S. McNeil, C.M. Lotem, M. Larkin, J.M. Lorigan, P. Neyns, B. Blank, C.U. Petrella, T.M. Hamid, O. Su, S.-. Krepler, C. Ibrahim, N. Long, G.V. (2019). Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. The lancet oncology, Vol.20 (9), pp. 1239-1251.

Regan, M.M. Werner, L. Rao, S. Gupte-Singh, K. Hodi, F.S. Kirkwood, J.M. Kluger, H.M. Larkin, J. Postow, M.A. Ritchings, C. Sznol, M. Tarhini, A.A. Wolchok, J.D. Atkins, M.B. McDermott, D.F. (2019). Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. , Vol.37 (35), pp. 3350-3358.  show abstract

Mason, R. Au, L. Ingles Garces, A. Larkin, J. (2019). Current and emerging systemic therapies for cutaneous metastatic melanoma. Expert opinion on pharmacotherapy, Vol.20 (9), pp. 1135-1152.

Buckley, H.L. Collinson, F.J. Ainsworth, G. Poad, H. Flanagan, L. Katona, E. Howard, H.C. Murden, G. Banks, R.E. Brown, J. Velikova, G. Waddell, T. Fife, K. Nathan, P.D. Larkin, J. Powles, T. Brown, S.R. Vasudev, N.S. (2019). PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. Bmc cancer, Vol.19 (1), pp. 1102-?.  show abstract

Larkin, J. Chiarion-Sileni, V. Gonzalez, R. Grob, J.-. Rutkowski, P. Lao, C.D. Cowey, C.L. Schadendorf, D. Wagstaff, J. Dummer, R. Ferrucci, P.F. Smylie, M. Hogg, D. Hill, A. Márquez-Rodas, I. Haanen, J. Guidoboni, M. Maio, M. Schöffski, P. Carlino, M.S. Lebbé, C. McArthur, G. Ascierto, P.A. Daniels, G.A. Long, G.V. Bastholt, L. Rizzo, J.I. Balogh, A. Moshyk, A. Hodi, F.S. Wolchok, J.D. (2019). Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New england journal of medicine, Vol.381 (16), pp. 1535-1546.

Motzer, R.J. Penkov, K. Haanen, J. Rini, B. Albiges, L. Campbell, M.T. Venugopal, B. Kollmannsberger, C. Negrier, S. Uemura, M. Lee, J.L. Vasiliev, A. Miller, W.H. Gurney, H. Schmidinger, M. Larkin, J. Atkins, M.B. Bedke, J. Alekseev, B. Wang, J. Mariani, M. Robbins, P.B. Chudnovsky, A. Fowst, C. Hariharan, S. Huang, B. di Pietro, A. Choueiri, T.K. (2019). Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New england journal of medicine, Vol.380 (12), pp. 1103-1115.

Valpione, S. Carlino, M.S. Mangana, J. Mooradian, M.J. McArthur, G. Schadendorf, D. Hauschild, A. Menzies, A.M. Arance, A. Ascierto, P.A. Di Giacomo, A. de Rosa, F. Larkin, J. Park, J.J. Goldinger, S.M. Sullivan, R.J. Xu, W. Livingstone, E. Weichenthal, M. Rai, R. Gaba, L. Long, G.V. Lorigan, P. (2018). Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. , Vol.91, pp. 116-124.  show abstract

Lim, K.H. Spain, L. Barker, C. Georgiou, A. Walls, G. Gore, M. Turajlic, S. Board, R. Larkin, J.M. Lorigan, P. (2018). Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. Esmo open, Vol.3 (2), pp. e000317-?.  show abstract

Flynn, M. Pickering, L. Larkin, J. Turajlic, S. (2018). Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Therapeutic advances in medical oncology, Vol.10, pp. 1758835918777427-?.  show abstract

Hauschild, A. Larkin, J. Ribas, A. Dréno, B. Flaherty, K.T. Ascierto, P.A. Lewis, K.D. McKenna, E. Zhu, Q. Mun, Y. McArthur, G.A. (2018). Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma. Jama oncology, Vol.4 (10), pp. 1382-1382.

Higham, C.E. Olsson-Brown, A. Carroll, P. Cooksley, T. Larkin, J. Lorigan, P. Morganstein, D. Trainer, P.J. Society for Endocrinology Clinical Committee, (2018). SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy. , Vol.7 (7), pp. G1-G7.  show abstract

Larkin, J. Minor, D. D'Angelo, S. Neyns, B. Smylie, M. Miller, W.H. Gutzmer, R. Linette, G. Chmielowski, B. Lao, C.D. Lorigan, P. Grossmann, K. Hassel, J.C. Sznol, M. Daud, A. Sosman, J. Khushalani, N. Schadendorf, D. Hoeller, C. Walker, D. Kong, G. Horak, C. Weber, J. (2018). Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of clinical oncology : official journal of the american society of clinical oncology, Vol.36 (4), pp. 383-390.  show abstract

Grob, J.J. Schadendorf, D. Lorigan, P. Ascierto, P. Larkin, J. Nathan, P. Robert, C. Hauschild, A. Weber, J. Daud, A. Hamid, O. Dummer, R. Hansson, J. Hoeller, C. Schachter, J. Van Akkooi, A.C. Garbe, C. (2018). Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. European journal of cancer (oxford, england : 1990), Vol.91, pp. 168-170.

Yip, K. Melcher, A. Harrington, K. Illidge, T. Nobes, J. Webster, A. Smith, D. Lorigan, P. Nathan, P. Larkin, J. (2018). Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial. Clinical oncology (royal college of radiologists (great britain)), Vol.30 (4), pp. 201-203.

Choueiri, T.K. Larkin, J. Oya, M. Thistlethwaite, F. Martignoni, M. Nathan, P. Powles, T. McDermott, D. Robbins, P.B. Chism, D.D. Cho, D. Atkins, M.B. Gordon, M.S. Gupta, S. Uemura, H. Tomita, Y. Compagnoni, A. Fowst, C. di Pietro, A. Rini, B.I. (2018). Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. The lancet oncology, Vol.19 (4), pp. 451-460.

Arce Vargas, F. Furness, A.J. Litchfield, K. Joshi, K. Rosenthal, R. Ghorani, E. Solomon, I. Lesko, M.H. Ruef, N. Roddie, C. Henry, J.Y. Spain, L. Ben Aissa, A. Georgiou, A. Wong, Y.N. Smith, M. Strauss, D. Hayes, A. Nicol, D. O'Brien, T. Mårtensson, L. Ljungars, A. Teige, I. Frendéus, B. TRACERx Melanoma, TRACERx Renal, TRACERx Lung consortia, Pule, M. Marafioti, T. Gore, M. Larkin, J. Turajlic, S. Swanton, C. Peggs, K.S. Quezada, S.A. (2018). Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer cell, Vol.33 (4), pp. 649-663.e4.  show abstract

Wongchenko, M.J. Ribas, A. Dréno, B. Ascierto, P.A. McArthur, G.A. Gallo, J.D. Rooney, I.A. Hsu, J. Koeppen, H. Yan, Y. Larkin, J. (2018). Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. Pigment cell & melanoma research, Vol.31 (4), pp. 516-522.  show abstract

Lyon, A.R. Yousaf, N. Battisti, N.M. Moslehi, J. Larkin, J. (2018). Immune checkpoint inhibitors and cardiovascular toxicity. The lancet oncology, Vol.19 (9), pp. e447-e458.

Sun, M. Marconi, L. Eisen, T. Escudier, B. Giles, R.H. Haas, N.B. Harshman, L.C. Quinn, D.I. Larkin, J. Pal, S.K. Powles, T. Ryan, C.W. Sternberg, C.N. Uzzo, R. Choueiri, T.K. Bex, A. (2018). Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. European urology, Vol.74 (5), pp. 611-620.

Smith, M.J. Smith, H.G. Joshi, K. Gore, M. Strauss, D.C. Hayes, A.J. Larkin, J. (2018). The impact of effective systemic therapies on surgery for stage IV melanoma. European journal of cancer, Vol.103, pp. 24-31.

Hodi, F.S. Chiarion-Sileni, V. Gonzalez, R. Grob, J.-. Rutkowski, P. Cowey, C.L. Lao, C.D. Schadendorf, D. Wagstaff, J. Dummer, R. Ferrucci, P.F. Smylie, M. Hill, A. Hogg, D. Marquez-Rodas, I. Jiang, J. Rizzo, J. Larkin, J. Wolchok, J.D. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. The lancet oncology, Vol.19 (11), pp. 1480-1492.

Wongchenko, M.J. Ribas, A. Ascierto, P.A. Dréno, B. Maria di Giacomo, A. Garbe, C. Chang, I. Hsu, J. Rooney, I. Lu, W. Koeppen, H. Larkin, J. Yan, Y. McArthur, G.A. (2018). Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study. Jco precision oncology, (2), pp. 1-18.  show abstract

Lu, W. Burton, L. Larkin, J. Chapman, P.B. Ascierto, P.A. Ribas, A. Robert, C. Sosman, J.A. McArthur, G.A. Chang, I. Caro, I. Penuel, E. Yan, Y. Wongchenko, M.J. (2018). Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. Jco precision oncology, (2), pp. 1-17.  show abstract

Turajlic, S. Xu, H. Litchfield, K. Rowan, A. Horswell, S. Chambers, T. O'Brien, T. Lopez, J.I. Watkins, T.B. Nicol, D. Stares, M. Challacombe, B. Hazell, S. Chandra, A. Mitchell, T.J. Au, L. Eichler-Jonsson, C. Jabbar, F. Soultati, A. Chowdhury, S. Rudman, S. Lynch, J. Fernando, A. Stamp, G. Nye, E. Stewart, A. Xing, W. Smith, J.C. Escudero, M. Huffman, A. Matthews, N. Elgar, G. Phillimore, B. Costa, M. Begum, S. Ward, S. Salm, M. Boeing, S. Fisher, R. Spain, L. Navas, C. Grönroos, E. Hobor, S. Sharma, S. Aurangzeb, I. Lall, S. Polson, A. Varia, M. Horsfield, C. Fotiadis, N. Pickering, L. Schwarz, R.F. Silva, B. Herrero, J. Luscombe, N.M. Jamal-Hanjani, M. Rosenthal, R. Birkbak, N.J. Wilson, G.A. Pipek, O. Ribli, D. Krzystanek, M. Csabai, I. Szallasi, Z. Gore, M. McGranahan, N. Van Loo, P. Campbell, P. Larkin, J. Swanton, C. TRACERx Renal Consortium, (2018). Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell, Vol.173 (3), pp. 595-610.e11.  show abstract

Turajlic, S. Xu, H. Litchfield, K. Rowan, A. Chambers, T. Lopez, J.I. Nicol, D. O'Brien, T. Larkin, J. Horswell, S. Stares, M. Au, L. Jamal-Hanjani, M. Challacombe, B. Chandra, A. Hazell, S. Eichler-Jonsson, C. Soultati, A. Chowdhury, S. Rudman, S. Lynch, J. Fernando, A. Stamp, G. Nye, E. Jabbar, F. Spain, L. Lall, S. Guarch, R. Falzon, M. Proctor, I. Pickering, L. Gore, M. Watkins, T.B. Ward, S. Stewart, A. DiNatale, R. Becerra, M.F. Reznik, E. Hsieh, J.J. Richmond, T.A. Mayhew, G.F. Hill, S.M. McNally, C.D. Jones, C. Rosenbaum, H. Stanislaw, S. Burgess, D.L. Alexander, N.R. Swanton, C. PEACE, TRACERx Renal Consortium, (2018). Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell, Vol.173 (3), pp. 581-594.e12.  show abstract

Hauschild, A. Dummer, R. Schadendorf, D. Santinami, M. Atkinson, V. Mandalà, M. Chiarion-Sileni, V. Larkin, J. Nyakas, M. Dutriaux, C. Haydon, A. Robert, C. Mortier, L. Schachter, J. Lesimple, T. Plummer, R. Dasgupta, K. Haas, T. Shilkrut, M. Gasal, E. Kefford, R. Kirkwood, J.M. Long, G.V. (2018). Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. Journal of clinical oncology : official journal of the american society of clinical oncology, Vol.36 (35), pp. 3441-3449.  show abstract

Grob, J.J. Garbe, C. Ascierto, P. Larkin, J. Dummer, R. Schadendorf, D. (2018). Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?. The lancet oncology, Vol.19 (12), pp. e720-e725.

Mitchell, T.J. Turajlic, S. Rowan, A. Nicol, D. Farmery, J.H. O'Brien, T. Martincorena, I. Tarpey, P. Angelopoulos, N. Yates, L.R. Butler, A.P. Raine, K. Stewart, G.D. Challacombe, B. Fernando, A. Lopez, J.I. Hazell, S. Chandra, A. Chowdhury, S. Rudman, S. Soultati, A. Stamp, G. Fotiadis, N. Pickering, L. Au, L. Spain, L. Lynch, J. Stares, M. Teague, J. Maura, F. Wedge, D.C. Horswell, S. Chambers, T. Litchfield, K. Xu, H. Stewart, A. Elaidi, R. Oudard, S. McGranahan, N. Csabai, I. Gore, M. Futreal, P.A. Larkin, J. Lynch, A.G. Szallasi, Z. Swanton, C. Campbell, P.J. TRACERx Renal Consortium, (2018). Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. , Vol.173 (3), pp. 611-623.e17.  show abstract

Proskorovsky, I. Benedict, A. Negrier, S. Bargo, D. Sandin, R. Ramaswamy, K. Desai, J. Cappelleri, J.C. Larkin, J. (2018). Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses. , Vol.18 (1), p. 1271.  show abstract

Dréno, B. Ascierto, P.A. Atkinson, V. Liszkay, G. Maio, M. Mandalà, M. Demidov, L. Stroyakovskiy, D. Thomas, L. de la Cruz-Merino, L. Dutriaux, C. Garbe, C. Bartley, K. Karagiannis, T. Chang, I. Rooney, I. Koralek, D.O. Larkin, J. McArthur, G.A. Ribas, A. (2018). Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma. , Vol.118 (6), pp. 777-784.  show abstract

Spain, L. Walls, G. Messiou, C. Turajlic, S. Gore, M. Larkin, J. (2017). Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. Cancer immunology, immunotherapy : cii, Vol.66 (1), pp. 113-117.  show abstract

Chapman, P.B. Robert, C. Larkin, J. Haanen, J.B. Ribas, A. Hogg, D. Hamid, O. Ascierto, P.A. Testori, A. Lorigan, P.C. Dummer, R. Sosman, J.A. Flaherty, K.T. Chang, I. Coleman, S. Caro, I. Hauschild, A. McArthur, G.A. (2017). Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann oncol, Vol.28 (10), pp. 2581-2587.  show abstract

D'Angelo, S.P. Larkin, J. Sosman, J.A. Lebbé, C. Brady, B. Neyns, B. Schmidt, H. Hassel, J.C. Hodi, F.S. Lorigan, P. Savage, K.J. Miller, W.H. Mohr, P. Marquez-Rodas, I. Charles, J. Kaatz, M. Sznol, M. Weber, J.S. Shoushtari, A.N. Ruisi, M. Jiang, J. Wolchok, J.D. (2017). Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of clinical oncology : official journal of the american society of clinical oncology, Vol.35 (2), pp. 226-235.  show abstract

Bridgeman, V.L. Vermeulen, P.B. Foo, S. Bilecz, A. Daley, F. Kostaras, E. Nathan, M.R. Wan, E. Frentzas, S. Schweiger, T. Hegedus, B. Hoetzenecker, K. Renyi-Vamos, F. Kuczynski, E.A. Vasudev, N.S. Larkin, J. Gore, M. Dvorak, H.F. Paku, S. Kerbel, R.S. Dome, B. Reynolds, A.R. (2017). Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. The journal of pathology, Vol.241 (3), pp. 362-374.  show abstract

Spain, L. Walls, G. Julve, M. O'Meara, K. Schmid, T. Kalaitzaki, E. Turajlic, S. Gore, M. Rees, J. Larkin, J. (2017). Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Annals of oncology : official journal of the european society for medical oncology, Vol.28 (2), pp. 377-385.  show abstract

O'Reilly, A. Larkin, J. (2017). Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. Expert review of clinical pharmacology, Vol.10 (3), pp. 251-262.  show abstract

Bracarda, S. Negrier, S. Casper, J. Porta, C. Schmidinger, M. Larkin, J. Gross Goupil, M. Escudier, B. (2017). How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. Expert review of anticancer therapy, Vol.17 (3), pp. 227-233.  show abstract

Weber, J.S. Hodi, F.S. Wolchok, J.D. Topalian, S.L. Schadendorf, D. Larkin, J. Sznol, M. Long, G.V. Li, H. Waxman, I.M. Jiang, J. Robert, C. (2017). Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. Journal of clinical oncology : official journal of the american society of clinical oncology, Vol.35 (7), pp. 785-792.  show abstract

Morganstein, D.L. Lai, Z. Spain, L. Diem, S. Levine, D. Mace, C. Gore, M. Larkin, J. (2017). Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clinical endocrinology, Vol.86 (4), pp. 614-620.  show abstract

Spain, L. Schmid, T. Gore, M. Larkin, J. (2017). Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features. European journal of cancer (oxford, england : 1990), Vol.75, pp. 243-244.

Rothermundt, C. von Rappard, J. Eisen, T. Escudier, B. Grünwald, V. Larkin, J. McDermott, D. Oldenburg, J. Porta, C. Rini, B. Schmidinger, M. Sternberg, C.N. Putora, P.M. (2017). Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms. World journal of urology, Vol.35 (4), pp. 641-648.  show abstract

Bowyer, S. Prithviraj, P. Lorigan, P. Larkin, J. McArthur, G. Atkinson, V. Millward, M. Khou, M. Diem, S. Ramanujam, S. Kong, B. Liniker, E. Guminski, A. Parente, P. Andrews, M.C. Parakh, S. Cebon, J. Long, G.V. Carlino, M.S. Klein, O. (2017). Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. British journal of cancer, Vol.116 (8), pp. e15-?.

Dréno, B. Ribas, A. Larkin, J. Ascierto, P.A. Hauschild, A. Thomas, L. Grob, J.-. Koralek, D.O. Rooney, I. Hsu, J.J. McKenna, E.F. McArthur, G.A. (2017). Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Annals of oncology : official journal of the european society for medical oncology, Vol.28 (5), pp. 1137-1144.  show abstract

Larkin, J. Chmielowski, B. Lao, C.D. Hodi, F.S. Sharfman, W. Weber, J. Suijkerbuijk, K.P. Azevedo, S. Li, H. Reshef, D. Avila, A. Reardon, D.A. (2017). Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. The oncologist, Vol.22 (6), pp. 709-718.  show abstract

Stewart, G.D. Aitchison, M. Bex, A. Larkin, J. Lawless, C. Méjean, A. Nathan, P. Oades, G. Patard, J.-. Paul, J. Ravaud, A. Escudier, B. Renal Cross Channel Group, (2017). Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered. European urology, Vol.71 (6), pp. 845-847.  show abstract

O'reilly, A. Larkin, J. (2017). Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. Expert review of anticancer therapy, Vol.17 (7), pp. 647-655.  show abstract

Helgadottir, H. Kis, L. Ljungman, P. Larkin, J. Kefford, R. Ascierto, P.A. Hansson, J. Masucci, G. (2017). Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. Annals of oncology : official journal of the european society for medical oncology, Vol.28 (7), pp. 1672-1673.

Blank, C.U. Larkin, J. Arance, A.M. Hauschild, A. Queirolo, P. Del Vecchio, M. Ascierto, P.A. Krajsova, I. Schachter, J. Neyns, B. Garbe, C. Chiarion Sileni, V. Mandalà, M. Gogas, H. Espinosa, E. Hospers, G.A. Miller, W.H. Robson, S. Makrutzki, M. Antic, V. Brown, M.P. (2017). Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. European journal of cancer (oxford, england : 1990), Vol.79, pp. 176-184.  show abstract

Long, G.V. Flaherty, K.T. Stroyakovskiy, D. Gogas, H. Levchenko, E. de Braud, F. Larkin, J. Garbe, C. Jouary, T. Hauschild, A. Chiarion-Sileni, V. Lebbe, C. Mandalà, M. Millward, M. Arance, A. Bondarenko, I. Haanen, J.B. Hansson, J. Utikal, J. Ferraresi, V. Mohr, P. Probachai, V. Schadendorf, D. Nathan, P. Robert, C. Ribas, A. Davies, M.A. Lane, S.R. Legos, J.J. Mookerjee, B. Grob, J.-. (2017). Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of oncology : official journal of the european society for medical oncology, Vol.28 (7), pp. 1631-1639.  show abstract

Colomba, E. Le Teuff, G. Eisen, T. Stewart, G.D. Fife, K. Larkin, J. Biondo, A. Pickering, L. Srinivasan, A. Boyle, H. Derosa, L. Sternberg, C.N. Recine, F. Ralph, C. Saldana, C. Barthélémy, P. Bernhard, J.C. Gurney, H. Verhoest, G. Vauleon, E. Bigot, P. Berger, J. Pfister, C. Gravis, G. Rodier, J.-. Culine, S. Caty, A. Rolland, F. Priou, F. Escudier, B. Albiges, L. (2017). Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. European journal of cancer (oxford, england : 1990), Vol.80, pp. 55-62.  show abstract

Haanen, J.B. Carbonnel, F. Robert, C. Kerr, K.M. Peters, S. Larkin, J. Jordan, K. ESMO Guidelines Committee, (2017). Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the european society for medical oncology, Vol.28 (suppl_4), pp. iv119-iv142.

Turajlic, S. Litchfield, K. Xu, H. Rosenthal, R. McGranahan, N. Reading, J.L. Wong, Y.N. Rowan, A. Kanu, N. Al Bakir, M. Chambers, T. Salgado, R. Savas, P. Loi, S. Birkbak, N.J. Sansregret, L. Gore, M. Larkin, J. Quezada, S.A. Swanton, C. (2017). Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. The lancet. oncology, Vol.18 (8), pp. 1009-1021.  show abstract

Matoori, S. Thian, Y. Koh, D.-. Sohaib, A. Larkin, J. Pickering, L. Gutzeit, A. (2017). Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients. Translational oncology, Vol.10 (4), pp. 679-685.  show abstract

O'Reilly, A. Larkin, J. (2017). The safety of nivolumab for the treatment of metastatic melanoma. Expert opinion on drug safety, Vol.16 (8), pp. 955-961.  show abstract

Wongchenko, M.J. McArthur, G.A. Dréno, B. Larkin, J. Ascierto, P.A. Sosman, J. Andries, L. Kockx, M. Hurst, S.D. Caro, I. Rooney, I. Hegde, P.S. Molinero, L. Yue, H. Chang, I. Amler, L. Yan, Y. Ribas, A. (2017). Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clinical cancer research : an official journal of the american association for cancer research, Vol.23 (17), pp. 5238-5245.  show abstract

Scelo, G. Purdue, M.P. Brown, K.M. Johansson, M. Wang, Z. Eckel-Passow, J.E. Ye, Y. Hofmann, J.N. Choi, J. Foll, M. Gaborieau, V. Machiela, M.J. Colli, L.M. Li, P. Sampson, J.N. Abedi-Ardekani, B. Besse, C. Blanche, H. Boland, A. Burdette, L. Chabrier, A. Durand, G. Le Calvez-Kelm, F. Prokhortchouk, E. Robinot, N. Skryabin, K.G. Wozniak, M.B. Yeager, M. Basta-Jovanovic, G. Dzamic, Z. Foretova, L. Holcatova, I. Janout, V. Mates, D. Mukeriya, A. Rascu, S. Zaridze, D. Bencko, V. Cybulski, C. Fabianova, E. Jinga, V. Lissowska, J. Lubinski, J. Navratilova, M. Rudnai, P. Szeszenia-Dabrowska, N. Benhamou, S. Cancel-Tassin, G. Cussenot, O. Baglietto, L. Boeing, H. Khaw, K.-. Weiderpass, E. Ljungberg, B. Sitaram, R.T. Bruinsma, F. Jordan, S.J. Severi, G. Winship, I. Hveem, K. Vatten, L.J. Fletcher, T. Koppova, K. Larsson, S.C. Wolk, A. Banks, R.E. Selby, P.J. Easton, D.F. Pharoah, P. Andreotti, G. Freeman, L.E. Koutros, S. Albanes, D. Männistö, S. Weinstein, S. Clark, P.E. Edwards, T.L. Lipworth, L. Gapstur, S.M. Stevens, V.L. Carol, H. Freedman, M.L. Pomerantz, M.M. Cho, E. Kraft, P. Preston, M.A. Wilson, K.M. Michael Gaziano, J. Sesso, H.D. Black, A. Freedman, N.D. Huang, W.-. Anema, J.G. Kahnoski, R.J. Lane, B.R. Noyes, S.L. Petillo, D. Teh, B.T. Peters, U. White, E. Anderson, G.L. Johnson, L. Luo, J. Buring, J. Lee, I.-. Chow, W.-. Moore, L.E. Wood, C. Eisen, T. Henrion, M. Larkin, J. Barman, P. Leibovich, B.C. Choueiri, T.K. Mark Lathrop, G. Rothman, N. Deleuze, J.-. McKay, J.D. Parker, A.S. Wu, X. Houlston, R.S. Brennan, P. Chanock, S.J. (2017). Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nature communications, Vol.8, pp. 15724-?.  show abstract

Schadendorf, D. Larkin, J. Wolchok, J. Hodi, F.S. Chiarion-Sileni, V. Gonzalez, R. Rutkowski, P. Grob, J.-. Cowey, C.L. Lao, C. Wagstaff, J. Callahan, M.K. Postow, M.A. Smylie, M. Ferrucci, P.F. Dummer, R. Hill, A. Taylor, F. Sabater, J. Walker, D. Kotapati, S. Abernethy, A. Long, G.V. (2017). Health-related quality of life results from the phase III CheckMate 067 study. European journal of cancer (oxford, england : 1990), Vol.82, pp. 80-91.  show abstract

Ugurel, S. Röhmel, J. Ascierto, P.A. Flaherty, K.T. Grob, J.J. Hauschild, A. Larkin, J. Long, G.V. Lorigan, P. McArthur, G.A. Ribas, A. Robert, C. Schadendorf, D. Garbe, C. (2017). Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. European journal of cancer (oxford, england : 1990), Vol.83, pp. 247-257.  show abstract

Hsieh, J.J. Purdue, M.P. Signoretti, S. Swanton, C. Albiges, L. Schmidinger, M. Heng, D.Y. Larkin, J. Ficarra, V. (2017). Renal cell carcinoma. Nature reviews. disease primers, Vol.3, pp. 17009-?.  show abstract

Schachter, J. Ribas, A. Long, G.V. Arance, A. Grob, J.-. Mortier, L. Daud, A. Carlino, M.S. McNeil, C. Lotem, M. Larkin, J. Lorigan, P. Neyns, B. Blank, C. Petrella, T.M. Hamid, O. Zhou, H. Ebbinghaus, S. Ibrahim, N. Robert, C. (2017). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet (london, england), Vol.390 (10105), pp. 1853-1862.  show abstract

Flynn, M.J. Larkin, J.M. (2017). Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. Expert opinion on pharmacotherapy, Vol.18 (14), pp. 1477-1490.  show abstract

Wolchok, J.D. Chiarion-Sileni, V. Gonzalez, R. Rutkowski, P. Grob, J.-. Cowey, C.L. Lao, C.D. Wagstaff, J. Schadendorf, D. Ferrucci, P.F. Smylie, M. Dummer, R. Hill, A. Hogg, D. Haanen, J. Carlino, M.S. Bechter, O. Maio, M. Marquez-Rodas, I. Guidoboni, M. McArthur, G. Lebbé, C. Ascierto, P.A. Long, G.V. Cebon, J. Sosman, J. Postow, M.A. Callahan, M.K. Walker, D. Rollin, L. Bhore, R. Hodi, F.S. Larkin, J. (2017). Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The new england journal of medicine, Vol.377 (14), pp. 1345-1356.  show abstract

Arce Vargas, F. Furness, A.J. Solomon, I. Joshi, K. Mekkaoui, L. Lesko, M.H. Miranda Rota, E. Dahan, R. Georgiou, A. Sledzinska, A. Ben Aissa, A. Franz, D. Werner Sunderland, M. Wong, Y.N. Henry, J.Y. O'Brien, T. Nicol, D. Challacombe, B. Beers, S.A. Melanoma TRACERx Consortium, Renal TRACERx Consortium, Lung TRACERx Consortium, Turajlic, S. Gore, M. Larkin, J. Swanton, C. Chester, K.A. Pule, M. Ravetch, J.V. Marafioti, T. Peggs, K.S. Quezada, S.A. (2017). Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, Vol.46 (4), pp. 577-586.  show abstract

Long, G.V. Weber, J.S. Larkin, J. Atkinson, V. Grob, J.-. Schadendorf, D. Dummer, R. Robert, C. Márquez-Rodas, I. McNeil, C. Schmidt, H. Briscoe, K. Baurain, J.-. Hodi, F.S. Wolchok, J.D. (2017). Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. Jama oncology, Vol.3 (11), pp. 1511-1519.  show abstract

Machiela, M.J. Hofmann, J.N. Carreras-Torres, R. Brown, K.M. Johansson, M. Wang, Z. Foll, M. Li, P. Rothman, N. Savage, S.A. Gaborieau, V. McKay, J.D. Ye, Y. Henrion, M. Bruinsma, F. Jordan, S. Severi, G. Hveem, K. Vatten, L.J. Fletcher, T. Koppova, K. Larsson, S.C. Wolk, A. Banks, R.E. Selby, P.J. Easton, D.F. Pharoah, P. Andreotti, G. Freeman, L.E. Koutros, S. Albanes, D. Mannisto, S. Weinstein, S. Clark, P.E. Edwards, T.E. Lipworth, L. Gapstur, S.M. Stevens, V.L. Carol, H. Freedman, M.L. Pomerantz, M.M. Cho, E. Kraft, P. Preston, M.A. Wilson, K.M. Gaziano, J.M. Sesso, H.S. Black, A. Freedman, N.D. Huang, W.-. Anema, J.G. Kahnoski, R.J. Lane, B.R. Noyes, S.L. Petillo, D. Colli, L.M. Sampson, J.N. Besse, C. Blanche, H. Boland, A. Burdette, L. Prokhortchouk, E. Skryabin, K.G. Yeager, M. Mijuskovic, M. Ognjanovic, M. Foretova, L. Holcatova, I. Janout, V. Mates, D. Mukeriya, A. Rascu, S. Zaridze, D. Bencko, V. Cybulski, C. Fabianova, E. Jinga, V. Lissowska, J. Lubinski, J. Navratilova, M. Rudnai, P. Szeszenia-Dabrowska, N. Benhamou, S. Cancel-Tassin, G. Cussenot, O. Bueno-de-Mesquita, H.B. Canzian, F. Duell, E.J. Ljungberg, B. Sitaram, R.T. Peters, U. White, E. Anderson, G.L. Johnson, L. Luo, J. Buring, J. Lee, I.-. Chow, W.-. Moore, L.E. Wood, C. Eisen, T. Larkin, J. Choueiri, T.K. Lathrop, G.M. Teh, B.T. Deleuze, J.-. Wu, X. Houlston, R.S. Brennan, P. Chanock, S.J. Scelo, G. Purdue, M.P. (2017). Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. European urology, Vol.72 (5), pp. 747-754.  show abstract

Long, G.V. Hauschild, A. Santinami, M. Atkinson, V. Mandalà, M. Chiarion-Sileni, V. Larkin, J. Nyakas, M. Dutriaux, C. Haydon, A. Robert, C. Mortier, L. Schachter, J. Schadendorf, D. Lesimple, T. Plummer, R. Ji, R. Zhang, P. Mookerjee, B. Legos, J. Kefford, R. Dummer, R. Kirkwood, J.M. (2017). Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. The new england journal of medicine, Vol.377 (19), pp. 1813-1823.  show abstract

Weber, J. Mandala, M. Del Vecchio, M. Gogas, H.J. Arance, A.M. Cowey, C.L. Dalle, S. Schenker, M. Chiarion-Sileni, V. Marquez-Rodas, I. Grob, J.-. Butler, M.O. Middleton, M.R. Maio, M. Atkinson, V. Queirolo, P. Gonzalez, R. Kudchadkar, R.R. Smylie, M. Meyer, N. Mortier, L. Atkins, M.B. Long, G.V. Bhatia, S. Lebbé, C. Rutkowski, P. Yokota, K. Yamazaki, N. Kim, T.M. de Pril, V. Sabater, J. Qureshi, A. Larkin, J. Ascierto, P.A. CheckMate 238 Collaborators, (2017). Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. The new england journal of medicine, Vol.377 (19), pp. 1824-1835.  show abstract

Schadendorf, D. Wolchok, J.D. Hodi, F.S. Chiarion-Sileni, V. Gonzalez, R. Rutkowski, P. Grob, J.-. Cowey, C.L. Lao, C.D. Chesney, J. Robert, C. Grossmann, K. McDermott, D. Walker, D. Bhore, R. Larkin, J. Postow, M.A. (2017). Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. Journal of clinical oncology : official journal of the american society of clinical oncology, Vol.35 (34), pp. 3807-3814.  show abstract

Grande, E. Glen, H. Aller, J. Argenziano, G. Lamas, M.J. Ruszniewski, P. Zamorano, J.L. Edmonds, K. Sarker, S. Staehler, M. Larkin, J. (2017). Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma. Expert opinion on drug safety, Vol.16 (12), pp. 1413-1426.  show abstract

Wolchok, J.D. Rollin, L. Larkin, J. (2017). Nivolumab and Ipilimumab in Advanced Melanoma. The new england journal of medicine, Vol.377 (25), pp. 2503-2504.

de la Cruz-Merino, L. Di Guardo, L. Grob, J.-. Venosa, A. Larkin, J. McArthur, G.A. Ribas, A. Ascierto, P.A. Evans, J.T. Gomez-Escobar, A. Barteselli, G. Eng, S. Hsu, J.J. Uyei, A. Dréno, B. (2017). Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. Journal of translational medicine, Vol.15 (1), pp. 146-?.  show abstract

Seifert, H. Hirata, E. Gore, M. Khabra, K. Messiou, C. Larkin, J. Sahai, E. (2016). Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases. Pigment cell & melanoma research, Vol.29 (1), pp. 92-100.

Bridgeman, V.L. Wan, E. Foo, S. Nathan, M.R. Welti, J.C. Frentzas, S. Vermeulen, P.B. Preece, N. Springer, C.J. Powles, T. Nathan, P.D. Larkin, J. Gore, M. Vasudev, N.S. Reynolds, A.R. (2016). Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. Molecular cancer therapeutics, Vol.15 (1), pp. 172-183.  show abstract

Atkins, M.B. Larkin, J. (2016). Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. Jnci: journal of the national cancer institute, Vol.108 (6).

Spain, L. Goode, E. McGovern, Y. Joshi, K. Larkin, J. (2016). The combination of vemurafenib and cobimetinib in advanced melanoma. Expert opinion on orphan drugs, Vol.4 (11), pp. 1105-1111 (7).

Ugurel, S. Röhmel, J. Ascierto, P.A. Flaherty, K.T. Grob, J.J. Hauschild, A. Larkin, J. Long, G.V. Lorigan, P. McArthur, G.A. Ribas, A. Robert, C. Schadendorf, D. Garbe, C. (2016). Survival of patients with advanced metastatic melanoma: The impact of novel therapies. European journal of cancer, Vol.53, pp. 125-134.

Motzer, R.J. Hutson, T.E. Ren, M. Dutcus, C. Larkin, J. (2016). Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. The lancet oncology, Vol.17 (1), pp. e4-e5.

Diem, S. Kasenda, B. Spain, L. Martin-Liberal, J. Marconcini, R. Gore, M. Larkin, J. (2016). Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. British journal of cancer, Vol.114 (3), pp. 256-261.

Spain, L. Julve, M. Larkin, J. (2016). Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations. Expert opinion on pharmacotherapy, Vol.17 (7), pp. 1031-1038.

Porta, C. Tortora, G. Larkin, J.M. Hutson, T.E. (2016). Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions. Future oncology, Vol.12 (4), pp. 533-549.  show abstract

Spain, L. Diem, S. Larkin, J. (2016). Management of toxicities of immune checkpoint inhibitors. Cancer treatment reviews, Vol.44, pp. 51-60.

Spain, L. Larkin, J. (2016). Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Expert opinion on biological therapy, Vol.16 (3), pp. 389-396.

Thomas, C.L. Mortimer, P.S. Larkin, J.M. Basu, T.N. Gore, M.E. Fearfield, L. (2016). A mitogen-activated protein kinase kinase inhibitor induced compound skin toxicity with oedema in metastatic malignant melanoma. Clinical and experimental dermatology, Vol.41 (3), pp. 267-271.

Seifert, H. Fisher, R. Martin-Liberal, J. Edmonds, K. Hughes, P. Khabra, K. Gore, M. Larkin, J. (2016). Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib. Melanoma research, Vol.26 (2), pp. 138-144.  show abstract

Gravis, G. Chanez, B. Derosa, L. Beuselinck, B. Barthelemy, P. Laguerre, B. Brachet, P.-. Joly, F. Escudier, B. Harrison, D.J. Laird, A. Vasudev, N. Ralph, C. Larkin, J. Lote, H. Salem, N. Walz, J. Thomassin, J. Sfumato, P. Stewart, G.D. Boher, J.M. Renal Cross Channel Group, (2016). Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. Urologic oncology, Vol.34 (4), pp. 167.e17-167.e23.  show abstract

Bowyer, S. Prithviraj, P. Lorigan, P. Larkin, J. McArthur, G. Atkinson, V. Millward, M. Khou, M. Diem, S. Ramanujam, S. Kong, B. Liniker, E. Guminski, A. Parente, P. Andrews, M.C. Parakh, S. Cebon, J. Long, G.V. Carlino, M.S. Klein, O. (2016). Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. British journal of cancer, Vol.114 (10), pp. 1084-1089.  show abstract

Powles, T. Brown, J. Larkin, J. Jones, R. Ralph, C. Hawkins, R. Chowdhury, S. Boleti, E. Bhal, A. Fife, K. Webb, A. Crabb, S. Geldart, T. Hill, R. Dunlop, J. Hall, P.E. McLaren, D. Ackerman, C. Beltran, L. Nathan, P. (2016). A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of oncology, Vol.27 (5), pp. 880-886.

Spain, L. Higgins, R. Gopalakrishnan, K. Turajlic, S. Gore, M. Larkin, J. (2016). Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Annals of oncology, Vol.27 (6), pp. 1135-1137.

Spain, L. Larkin, J. Martin-Liberal, J. (2016). Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome". Cancer immunology, immunotherapy : cii, Vol.65 (6), pp. 769-770.

Spain, L. Larkin, J. (2016). Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma. Immunotherapy, Vol.8 (6), pp. 677-679.

Rini, B.I. Dorff, T.B. Elson, P. Rodriguez, C.S. Shepard, D. Wood, L. Humbert, J. Pyle, L. Wong, Y.-. Finke, J.H. Rayman, P.A. Larkin, J.M. Garcia, J.A. Plimack, E.R. (2016). Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. The lancet. oncology, Vol.17 (9), pp. 1317-1324.  show abstract

Ascierto, P.A. McArthur, G.A. Dréno, B. Atkinson, V. Liszkay, G. Di Giacomo, A.M. Mandalà, M. Demidov, L. Stroyakovskiy, D. Thomas, L. de la Cruz-Merino, L. Dutriaux, C. Garbe, C. Yan, Y. Wongchenko, M. Chang, I. Hsu, J.J. Koralek, D.O. Rooney, I. Ribas, A. Larkin, J. (2016). Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. The lancet. oncology, Vol.17 (9), pp. 1248-1260.  show abstract

Turajlic, S. Larkin, J. (2016). Systemic treatment of advanced papillary renal cell carcinoma: Where next?. European journal of cancer (oxford, england : 1990), Vol.69, pp. 223-225.

Larkin, J. Lao, C.D. Urba, W.J. McDermott, D.F. Horak, C. Jiang, J. Wolchok, J.D. (2015). Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma. Jama oncology, Vol.1 (4), pp. 433-433.

Rothermundt, C. Bailey, A. Cerbone, L. Eisen, T. Escudier, B. Gillessen, S. Grünwald, V. Larkin, J. McDermott, D. Oldenburg, J. Porta, C. Rini, B. Schmidinger, M. Sternberg, C. Putora, P.M. (2015). Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma—Analysis Using Diagnostic Nodes. The oncologist, Vol.20 (9), pp. 1028-1035.  show abstract

Lorigan, P. Ascierto, P.A. Dummer, R. Eggermont, A.M. Flaherty, K.T. Garbe, C. Gogas, H. Hauschild, A. Kefford, R.F. Kirkwood, J.M. Larkin, J. Long, G.V. Maio, M. McArthur, G.A. Ribas, A. Robert, C. Schadendorf, D. Sondak, V.K. Wolchok, J.D. Hudson, A.M. (2015). Expanded access programmes: patient interests versus clinical trial integrity. Lancet oncology, Vol.16 (1), pp. 15-17.

Coupe, N. Corrie, P. Hategan, M. Larkin, J. Gore, M. Gupta, A. Wise, A. Suter, S. Ciria, C. Love, S. Collins, L. Middleton, M.R. (2015). PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. Eur j cancer, Vol.51 (3), pp. 359-366.  show abstract

Larkin, J. Paine, A. Foley, G. Mitchell, S. Chen, C. (2015). First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis. Expert opinion on pharmacotherapy, Vol.16 (13), pp. 1915-1927.

Larkin, J. Chiarion-Sileni, V. Gonzalez, R. Grob, J.J. Cowey, C.L. Lao, C.D. Schadendorf, D. Dummer, R. Smylie, M. Rutkowski, P. Ferrucci, P.F. Hill, A. Wagstaff, J. Carlino, M.S. Haanen, J.B. Maio, M. Marquez-Rodas, I. McArthur, G.A. Ascierto, P.A. Long, G.V. Callahan, M.K. Postow, M.A. Grossmann, K. Sznol, M. Dreno, B. Bastholt, L. Yang, A. Rollin, L.M. Horak, C. Hodi, F.S. Wolchok, J.D. (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New england journal of medicine, Vol.373 (1), pp. 23-34.

Martin-Liberal, J. Kordbacheh, T. Larkin, J. (2015). Safety of pembrolizumab for the treatment of melanoma. Expert opinion on drug safety, Vol.14 (6), pp. 957-964.

Sinha, R. Larkin, J. Fearfield, L. (2015). Clinical resolution of vemurafenib-induced squamous cell carcinoma with topical 5-fluorouracil. British journal of dermatology, Vol.172 (4), pp. 1135-1136.

Hirata, E. Girotti, M.R. Viros, A. Hooper, S. Spencer-Dene, B. Matsuda, M. Larkin, J. Marais, R. Sahai, E. (2015). Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling. Cancer cell, Vol.27 (4), pp. 574-588.

Weber, J.S. D'Angelo, S.P. Minor, D. Hodi, F.S. Gutzmer, R. Neyns, B. Hoeller, C. Khushalani, N.I. Miller, W.H. Lao, C.D. Linette, G.P. Thomas, L. Lorigan, P. Grossmann, K.F. Hassel, J.C. Maio, M. Sznol, M. Ascierto, P.A. Mohr, P. Chmielowski, B. Bryce, A. Svane, I.M. Grob, J.-. Krackhardt, A.M. Horak, C. Lambert, A. Yang, A.S. Larkin, J. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The lancet oncology, Vol.16 (4), pp. 375-384.

Kovac, M. Navas, C. Horswell, S. Salm, M. Bardella, C. Rowan, A. Stares, M. Castro-Giner, F. Fisher, R. de Bruin, E.C. Kovacova, M. Gorman, M. Makino, S. Williams, J. Jaeger, E. Jones, A. Howarth, K. Larkin, J. Pickering, L. Gore, M. Nicol, D.L. Hazell, S. Stamp, G. O’Brien, T. Challacombe, B. Matthews, N. Phillimore, B. Begum, S. Rabinowitz, A. Varela, I. Chandra, A. Horsfield, C. Polson, A. Tran, M. Bhatt, R. Terracciano, L. Eppenberger-Castori, S. Protheroe, A. Maher, E. El Bahrawy, M. Fleming, S. Ratcliffe, P. Heinimann, K. Swanton, C. Tomlinson, I. (2015). Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nature communications, Vol.6 (1).

Thomas, C.L. Mortimer, P.S. Larkin, J.M. Basu, T.N. Gore, M.E. Fearfield, L. (2015). MEK-inhibitor induced compound skin toxicity with oedema in metastatic malignant melanoma: a case series. Australasian journal of dermatology, Vol.56, pp. 78-78.

Bex, A. Larkin, J. Voss, M. (2015). Challenging the Treatment Paradigm for Advanced Renal Cell Carcinoma: A Review of Systemic and Localized Therapies. American society of clinical oncology educational book, (35), pp. e239-e247.  show abstract

Motzer, R.J. Escudier, B. McDermott, D.F. George, S. Hammers, H.J. Srinivas, S. Tykodi, S.S. Sosman, J.A. Procopio, G. Plimack, E.R. Castellano, D. Choueiri, T.K. Gurney, H. Donskov, F. Bono, P. Wagstaff, J. Gauler, T.C. Ueda, T. Tomita, Y. Schutz, F.A. Kollmannsberger, C. Larkin, J. Ravaud, A. Simon, J.S. Xu, L.-. Waxman, I.M. Sharma, P. (2015). Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New england journal of medicine, Vol.373 (19), pp. 1803-1813.

Schadendorf, D. Amonkar, M.M. Stroyakovskiy, D. Levchenko, E. Gogas, H. de Braud, F. Grob, J.-. Bondarenko, I. Garbe, C. Lebbe, C. Larkin, J. Chiarion-Sileni, V. Millward, M. Arance, A. Mandalà, M. Flaherty, K.T. Nathan, P. Ribas, A. Robert, C. Casey, M. DeMarini, D.J. Irani, J.G. Aktan, G. Long, G.V. (2015). Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. European journal of cancer, Vol.51 (7), pp. 833-840.

Yousaf, N. Davidson, M. Goode, E. Thomas, C. Hung, R. Gore, M. Larkin, J. (2015). The cost of ipilimumab toxicity. Melanoma research, Vol.25 (3), pp. 259-264.

Pickering, L.M. Larkin, J. (2015). Carbonic anhydrase IX in resected clear cell RCC. Nature reviews urology, Vol.12 (6), pp. 309-310.

Martin-Liberal, J. Furness, A.J. Joshi, K. Peggs, K.S. Quezada, S.A. Larkin, J. (2015). Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer immunology, immunotherapy, Vol.64 (6), pp. 765-767.

Gulati, S. Turajlic, S. Larkin, J. Bates, P.A. Swanton, C. (2015). Relapse models for clear cell renal carcinoma. The lancet oncology, Vol.16 (8), pp. e376-e378.

Long, G.V. Stroyakovskiy, D. Gogas, H. Levchenko, E. de Braud, F. Larkin, J. Garbe, C. Jouary, T. Hauschild, A. Grob, J.-. Chiarion-Sileni, V. Lebbe, C. Mandalà, M. Millward, M. Arance, A. Bondarenko, I. Haanen, J.B. Hansson, J. Utikal, J. Ferraresi, V. Kovalenko, N. Mohr, P. Probachai, V. Schadendorf, D. Nathan, P. Robert, C. Ribas, A. DeMarini, D.J. Irani, J.G. Swann, S. Legos, J.J. Jin, F. Mookerjee, B. Flaherty, K. (2015). Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. The lancet, Vol.386 (9992), pp. 444-451.

Wolchok, J.D. Chiarion-Sileni, V. Gonzalez, R. Rutkowski, P. Grob, J.J. Cowey, C.L. Lao, C.D. Schadendorf, D. Ferrucci, P.F. Smylie, M. Dummer, R. Hill, A. Haanen, J. Maio, M. McArthur, G. Yang, A. Rollin, L. Horak, C. Larkin, J. Hodi, F.S. (2015). CHECKMATE 067: A PHASE III RANDOMIZED DOUBLE-BLIND STUDY OF NIVOLUMAB (NIVO) MONOTHERAPY OR NIVO COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN PREVIOUSLY UNTREATED PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL). Asia-pacific journal of clinical oncology, Vol.11, pp. 68-68.

Soultati, A. Stares, M. Swanton, C. Larkin, J. Turajlic, S. (2015). How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?. Current opinion in urology, Vol.25 (5), pp. 358-366.

Moriceau, G. Hugo, W. Hong, A. Shi, H. Kong, X. Yu, C.C. Koya, R.C. Samatar, A.A. Khanlou, N. Braun, J. Ruchalski, K. Seifert, H. Larkin, J. Dahlman, K.B. Johnson, D.B. Algazi, A. Sosman, J.A. Ribas, A. Lo, R.S. (2015). Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer cell, Vol.27 (2), pp. 240-256.  show abstract

Sinha, R. Larkin, J. Gore, M. Fearfield, L. (2015). Cutaneous toxicities associated with vemurafenib therapy in 107 patients withBRAFV600E mutation-positive metastatic melanoma, including recognition and management of rare presentations. British journal of dermatology, Vol.173 (4), pp. 1024-1031.

Turajlic, S. Larkin, J. Swanton, C. (2015). Academically led clinical trials: challenges and opportunities. Annals of oncology, Vol.26 (10), pp. 2010-2011.

Motzer, R. Hutson, T. Glen, H. Michaelson, M.D. Molina, A. Eisen, T. Jassem, J. Zolnierek, J. Maroto, P. Mellado, B. Melichar, B. Tomasek, J. Kim, H.-. Wood, K. Dutcus, C. Larkin, J. (2015). Randomized phase 2 three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN plus EVE in patients (pts) with metastatic renal cell carcinoma (mRCC). Oncology research and treatment, Vol.38, pp. 203-204.

Ahmad, S.S. Qian, W. Ellis, S. Mason, E. Khattak, M.A. Gupta, A. Shaw, H. Quinton, A. Kovarikova, J. Thillai, K. Rao, A. Board, R. Nobes, J. Dalgleish, A. Grumett, S. Maraveyas, A. Danson, S. Talbot, T. Harries, M. Marples, M. Plummer, R. Kumar, S. Nathan, P. Middleton, M.R. Larkin, J. Lorigan, P. Wheater, M. Ottensmeier, C.H. Corrie, P.G. (2015). Ipilimumab in the real world. Melanoma research, Vol.25 (5), pp. 432-442.

Kanu, N. Grönroos, E. Martinez, P. Burrell, R.A. Yi Goh, X. Bartkova, J. Maya-Mendoza, A. Mistrík, M. Rowan, A.J. Patel, H. Rabinowitz, A. East, P. Wilson, G. Santos, C.R. McGranahan, N. Gulati, S. Gerlinger, M. Birkbak, N.J. Joshi, T. Alexandrov, L.B. Stratton, M.R. Powles, T. Matthews, N. Bates, P.A. Stewart, A. Szallasi, Z. Larkin, J. Bartek, J. Swanton, C. (2015). SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene, Vol.34 (46), pp. 5699-5708.

Wilkins, A. Furness, A. Corbett, R.W. Bloomfield, A. Porta, N. Morris, S. Ali, Z. Larkin, J. Harrington, K. (2015). The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma. British journal of cancer, Vol.113 (9), pp. 1275-1281.  show abstract

Motzer, R.J. Hutson, T.E. Glen, H. Michaelson, M.D. Molina, A. Eisen, T. Jassem, J. Zolnierek, J. Maroto, J.P. Mellado, B. Melichar, B. Tomasek, J. Kremer, A. Kim, H.-. Wood, K. Dutcus, C. Larkin, J. (2015). Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. The lancet oncology, Vol.16 (15), pp. 1473-1482.

Larkin, J. Chiarion-Sileni, V. Gonzalez, R. Grob, J.-. Cowey, C.L. Lao, C.D. Wagstaff, J. Hogg, D. Hill, A. Carlino, M.S. Wolter, P. Lebbe, C. Schachter, J. Thomas, L. Hassal, J.C. Lorigan, P. Walker, D. Jiang, J. Hodi, F.S. Wolchok, J.D. (2015). EFFICACY AND SAFETY IN KEY PATIENT SUBGROUPS OF NIVOLUMAB (NIVO) ALONE OR COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI ALONE IN TREATMENT-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) (CHECKMATE 067). Asia-pacific journal of clinical oncology, Vol.11, pp. 126-126.

Spain, L. Younger, E. Hatipoglu, E. Larkin, J. (2015). Pembrolizumab in the management of metastatic melanoma. Melanoma management, Vol.2 (4), pp. 315-325.  show abstract

Diem, S. Kasenda, B. Martin-Liberal, J. Lee, A. Chauhan, D. Gore, M. Larkin, J. (2015). Prognostic score for patients with advanced melanoma treated with ipilimumab. European journal of cancer, Vol.51 (18), pp. 2785-2791.

Turajlic, S. Larkin, J. Swanton, C. (2015). SnapShot: Renal Cell Carcinoma. Cell, Vol.163 (6), pp. 1556-1556.e1.

Gore, M. Larkin, J. (2015). Precision oncology: where next?. The lancet oncology, Vol.16 (16), pp. 1593-1595.

Dummer, R. Schadendorf, D. Ascierto, P.A. Larkin, J. Lebbé, C. Hauschild, A. (2015). Integrating first-line treatment options into clinical practice. Melanoma research, Vol.25 (6), pp. 461-469.

Richman, J. Martin-Liberal, J. Diem, S. Larkin, J. (2015). BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Expert opinion on pharmacotherapy, Vol.16 (9), pp. 1285-1297.

Jamal-Hanjani, M. Quezada, S.A. Larkin, J. Swanton, C. (2015). Translational Implications of Tumor Heterogeneity. Clinical cancer research, Vol.21 (6), pp. 1258-1266.  show abstract

Robert, C. Schachter, J. Long, G.V. Arance, A. Grob, J.J. Mortier, L. Daud, A. Carlino, M.S. McNeil, C. Lotem, M. Larkin, J. Lorigan, P. Neyns, B. Blank, C.U. Hamid, O. Mateus, C. Shapira-Frommer, R. Kosh, M. Zhou, H. Ibrahim, N. Ebbinghaus, S. Ribas, A. (2015). Pembrolizumab versus Ipilimumab in Advanced Melanoma. New england journal of medicine, Vol.372 (26), pp. 2521-2532.

Kasenda, B. Larkin, J. Gore, M. (2015). Immunotherapies in Early and Advanced Renal Cell Cancer. , , pp. 1-10.

Martin-Liberal, J. Larkin, J. (2015). Vemurafenib for the treatment of BRAF mutant metastatic melanoma. Future oncol, Vol.11 (4), pp. 579-589.  show abstract

Molina, A.M. Hutson, T.E. Larkin, J. Gold, A.M. Wood, K. Carter, D. Motzer, R. Michaelson, M.D. (2014). A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer chemotherapy and pharmacology, Vol.73 (1), pp. 181-189.

Gerlinger, M. Horswell, S. Larkin, J. Rowan, A.J. Salm, M.P. Varela, I. Fisher, R. McGranahan, N. Matthews, N. Santos, C. Martinez, P. Phillimore, B. Begum, S. Rabinowitz, A. Spencer-Dene, B. Gulati, S. Bates, P.A. Stamp, G. Pickering, L. Gore, M. Nicol, D.L. Hazell, S. Futreal, P.A. Stewart, A. Swanton, C. (2014). Genomic architecture and evolution of clear cell renal carcinomas defined by multiregion sequencing. Nature genetics, .  show abstract

Khattak, M. Larkin, J. (2014). Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance. World j urol, Vol.32 (1), pp. 19-29.  show abstract

McArthur, G.A. Chapman, P.B. Robert, C. Larkin, J. Haanen, J.B. Dummer, R. Ribas, A. Hogg, D. Hamid, O. Ascierto, P.A. Garbe, C. Testori, A. Maio, M. Lorigan, P. Lebbé, C. Jouary, T. Schadendorf, D. O'Day, S.J. Kirkwood, J.M. Eggermont, A.M. Dréno, B. Sosman, J.A. Flaherty, K.T. Yin, M. Caro, I. Cheng, S. Trunzer, K. Hauschild, A. (2014). Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet oncol, Vol.15 (3), pp. 323-332.  show abstract

Hutson, T.E. Bukowski, R.M. Rini, B.I. Gore, M.E. Larkin, J.M. Figlin, R.A. Barrios, C.H. Escudier, B. Lin, X. Fly, K. Martell, B. Matczak, E. Motzer, R.J. (2014). Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br j cancer, Vol.110 (5), pp. 1125-1132.  show abstract

Martin-Liberal, J. Lagares-Tena, L. Larkin, J. (2014). Prospects for MEK inhibitors for treating cancer. Expert opin drug saf, Vol.13 (4), pp. 483-495.  show abstract

Larkin, J. Del Vecchio, M. Ascierto, P.A. Krajsova, I. Schachter, J. Neyns, B. Espinosa, E. Garbe, C. Sileni, V.C. Gogas, H. Miller, W.H. Mandalà, M. Hospers, G.A. Arance, A. Queirolo, P. Hauschild, A. Brown, M.P. Mitchell, L. Veronese, L. Blank, C.U. (2014). Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet oncol, Vol.15 (4), pp. 436-444.  show abstract

Turajlic, S. Furney, S.J. Stamp, G. Rana, S. Ricken, G. Oduko, Y. Saturno, G. Springer, C. Hayes, A. Gore, M. Larkin, J. Marais, R. (2014). Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann oncol, Vol.25 (5), pp. 959-967.  show abstract

Kelderman, S. Heemskerk, B. van Tinteren, H. van den Brom, R.R. Hospers, G.A. van den Eertwegh, A.J. Kapiteijn, E.W. de Groot, J.W. Soetekouw, P. Jansen, R.L. Fiets, E. Furness, A.J. Renn, A. Krzystanek, M. Szallasi, Z. Lorigan, P. Gore, M.E. Schumacher, T.N. Haanen, J.B. Larkin, J.M. Blank, C.U. (2014). Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer immunology immunotherapy, Vol.63 (5), pp. 449-458.

Gupta, A. Love, S. Schuh, A. Shanyinde, M. Larkin, J.M. Plummer, R. Nathan, P.D. Danson, S. Ottensmeier, C.H. Lorigan, P. Collins, L. Wise, A. Asher, R. Lisle, R. Middleton, M.R. (2014). DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. Annals of oncology, Vol.25 (5), pp. 968-974.

Martin-Liberal, J. Larkin, J. (2014). New RAF kinase inhibitors in cancer therapy. Expert opin pharmacother, Vol.15 (9), pp. 1235-1245.  show abstract

Benson, C. Vitfell-Rasmussen, J. Maruzzo, M. Fisher, C. Tunariu, N. Mitchell, S. Al-Muderis, O. Thway, K. Larkin, J. Judson, I. (2014). A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer res, Vol.34 (7), pp. 3663-3668.  show abstract

Larkin, J. Fishman, M. Wood, L. Negrier, S. Olivier, K. Pyle, L. Gorbunova, V. Jonasch, E. Andrews, L. Staehler, M. (2014). Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes. Am j clin oncol, Vol.37 (4), pp. 397-403.  show abstract

Fisher, R. Horswell, S. Rowan, A. Salm, M.P. de Bruin, E.C. Gulati, S. McGranahan, N. Stares, M. Gerlinger, M. Varela, I. Crockford, A. Favero, F. Quidville, V. André, F. Navas, C. Grönroos, E. Nicol, D. Hazell, S. Hrouda, D. O'Brien, T. Matthews, N. Phillimore, B. Begum, S. Rabinowitz, A. Biggs, J. Bates, P.A. McDonald, N.Q. Stamp, G. Spencer-Dene, B. Hsieh, J.J. Xu, J. Pickering, L. Gore, M. Larkin, J. Swanton, C. (2014). Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome biology, Vol.15 (8), p. 433.  show abstract  full text

Ascierto, P.A. Larkin, J. (2014). Advances in immunotherapy for melanoma. Melanoma management, Vol.1 (1), pp. 19-24.  show abstract

Furney, S.J. Turajlic, S. Stamp, G. Thomas, J.M. Hayes, A. Strauss, D. Gavrielides, M. Xing, W. Gore, M. Larkin, J. Marais, R. (2014). The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment cell & melanoma research, Vol.27 (5), pp. 835-838.

Coupe, N. Corrie, P. Hategan, M. Larkin, J. Gore, M.E. Gupta, A. Wise, A. Suter, S. Ciria, C. Love, S. Collins, L. Middleton, M.R. (2014). A Phase 1, Dose Escalation Study of Paclitaxel with Gsk1120212 (Trametinib) for the Treatment of Advanced Melanoma. Annals of oncology, Vol.25, pp. iv379-iv379.

Schadendorf, D. Amonkar, M.M. Stroyakovskiy, D. Levchenko, E. Gogas, H. De Braud, F.G. Grob, J. Bondarenko, I. Garbe, C. Lebbe, C. Larkin, J. Chiarion-Sileni, V. Millward, M. Arance, A. Mandalà, M. Casey, M. Demarini, D.J. Irani, J. Aktan, G. Long, G.V. (2014). Combi-D: Quality of Life (Qol) Impact of the Combination of Dabrafenib and Trametinib (D + T) Versus Dabrafenib Monotherapy (D) in Patients with Braf V600E/K Unresectable or Metastatic Melanoma in a Phase III Trial. Annals of oncology, Vol.25, pp. iv377-iv377.

Gravis, G. Chanez, B. Derosa, L. Beuselinck, B. Laguerre, B. Barthelemy, P. Brachet, P.E. Lobbedez, F.J. Escudier, B. Stewart, G.D. Harrison, D. Laird, A. Vasudev, N. Ralph, C. Larkin, J. Lote, H. Walz, J. Thomassin, J. Salem, N. Boher, J.M. (2014). Impact on Overall Survival of Glandular Metastasis in Patients with Metastatic Clear Cell Renal Cell Carcinoma on Behalf of the Renal Cross Channel Group. Annals of oncology, Vol.25, pp. iv286-iv286.

Larkin, J. Okines, A. (2014). Precision Medicine in Kidney Cancer and Clinical Trial Designs. Annals of oncology, Vol.25, pp. iv17-iv17.

Nobbenhuis, M.A. Lalondrelle, S. Larkin, J. Banerjee, S. (2014). Management of melanomas of the gynaecological tract. Curr opin oncol, Vol.26 (5), pp. 508-513.  show abstract

Pickering, L. Larkin, J. (2014). Systemic anti-cancer therapy (SACT) dataset. The lancet oncology, Vol.15 (10), pp. 1063-1063.

Leijen, S. Barlesi, F. Eberhardt, W.E. Martinez, G.M. Dieras, V. Schellens, J.H. Middleton, M. Calvo, E. Paz-Ares, L. Larkin, J. Jodrell, D. Soria, J.C. (2014). OCULAR TOXICITIES OBSERVED WITH MEK INHIBITOR RO4987655 (CH4987655) IN A SINGLE AGENT PHASE I STUDY WITH EXTENSION IN PATIENTS WITH ADVANCED SOLID TUMORS. British journal of clinical pharmacology, Vol.78 (4), pp. 769-769.

Thian, Y. Gutzeit, A. Koh, D.-. Fisher, R. Lote, H. Larkin, J. Sohaib, A. (2014). Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib. Radiology, Vol.273 (2), pp. 452-461.  show abstract

Kenny, L.M. Tomasi, G. Turkheimer, F. Larkin, J. Gore, M. Brock, C.S. Mangar, S. Aboagye, E.O. (2014). Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [18F]fluciclatide kinetics and [15O]H2O PET. Ejnmmi research, Vol.4 (1).

Larkin, J. Ascierto, P.A. Dréno, B. Atkinson, V. Liszkay, G. Maio, M. Mandalà, M. Demidov, L. Stroyakovskiy, D. Thomas, L. de la Cruz-Merino, L. Dutriaux, C. Garbe, C. Sovak, M.A. Chang, I. Choong, N. Hack, S.P. McArthur, G.A. Ribas, A. (2014). Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N engl j med, Vol.371 (20), pp. 1867-1876.  show abstract

Long, G.V. Stroyakovskiy, D. Gogas, H. Levchenko, E. de Braud, F. Larkin, J. Garbe, C. Jouary, T. Hauschild, A. Grob, J.J. Sileni, V.C. Lebbe, C. Mandala, M. Millward, M. Arance, A. Bondarenko, I. Haanen, J.B. Hansson, J. Utikal, J. Ferraresi, V. Kovalenko, N. Mohr, P. Probachai, V. Schadendorf, D. Nathan, P. Robert, C. Ribas, A. DeMarini, D.J. Irani, J.G. Casey, M. Ouellet, D. Martin, A.-. Le, N. Patel, K. Flaherty, K. (2014). Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. New england journal of medicine, Vol.371 (20), pp. 1877-1888.

Antonia, S.J. Larkin, J. Ascierto, P.A. (2014). Immuno-oncology combinations: a review of clinical experience and future prospects. Clin cancer res, Vol.20 (24), pp. 6258-6268.  show abstract

Zimmer, L. Barlesi, F. Martinez-Garcia, M. Dieras, V. Schellens, J.H. Spano, J.-. Middleton, M.R. Calvo, E. Paz-Ares, L. Larkin, J. Pacey, S. Venturi, M. Kraeber-Bodéré, F. Tessier, J.J. Eberhardt, W.E. Paques, M. Guarin, E. Meresse, V. Soria, J.-. (2014). Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clin cancer res, Vol.20 (16), pp. 4251-4261.  show abstract

Sanchez-Laorden, B. Viros, A. Girotti, M.R. Pedersen, M. Saturno, G. Zambon, A. Niculescu-Duvaz, D. Turajlic, S. Hayes, A. Gore, M. Larkin, J. Lorigan, P. Cook, M. Springer, C. Marais, R. (2014). BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells By Reactivating MEK and ERK Signaling. Science signaling, Vol.7 (318).

Ascierto, P.A. Grimaldi, A.M. Anderson, A.C. Bifulco, C. Cochran, A. Garbe, C. Eggermont, A.M. Faries, M. Ferrone, S. Gershenwald, J.E. Gajewski, T.F. Halaban, R. Hodi, F.S. Kefford, R. Kirkwood, J.M. Larkin, J. Leachman, S. Maio, M. Marais, R. Masucci, G. Melero, I. Palmieri, G. Puzanov, I. Ribas, A. Saenger, Y. Schilling, B. Seliger, B. Stroncek, D. Sullivan, R. Testori, A. Wang, E. Ciliberto, G. Mozzillo, N. Marincola, F.M. Thurin, M. (2014). Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. Journal of translational medicine, Vol.12.

Khattak, M.A. Bakr, F. Krzystanek, M. Szallasi, Z. Gerlinger, M. Santos, C. Swanton, C. Pickering, L.M. Gore, M.E. Larkin, J.M. (2013). Prognostic and predictive markers in metastatic renal cell carcinoma. J clin oncol, Vol.31 (7), pp. 971-972.

Sinha, R. Edmonds, K. Newton-Bishop, J. Gore, M. Larkin, J. Fearfield, L. (2013). Erythema Nodosum-Like Panniculitis in Patients With Melanoma Treated With Vemurafenib. Journal of clinical oncology, Vol.31 (19), pp. E320-E321.

Larkin, J. Paine, A. Tumur, I. Cappelleri, J.C. Healey, P.J. Foley, G. Mitchell, S. Kroes, M. Chen, C. (2013). Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis. Expert opin pharmacother, Vol.14 (1), pp. 27-39.  show abstract

Khattak, M.A. Fisher, R. Hughes, P. Gore, M. Larkin, J. (2013). Ipilimumab activity in advanced uveal melanoma. Melanoma res, Vol.23 (1), pp. 79-81.  show abstract

Fisher, R. Gore, M. Larkin, J. (2013). Current and future systemic treatments for renal cell carcinoma. Semin cancer biol, Vol.23 (1), pp. 38-45.  show abstract

Girotti, M.R. Pedersen, M. Sanchez-Laorden, B. Viros, A. Turajlic, S. Niculescu-Duvaz, D. Zambon, A. Sinclair, J. Hayes, A. Gore, M. Lorigan, P. Springer, C. Larkin, J. Jorgensen, C. Marais, R. (2013). Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer discov, Vol.3 (2), pp. 158-167.  show abstract

Khattak, M. Fisher, R. Turajlic, S. Larkin, J. (2013). Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther adv med oncol, Vol.5 (2), pp. 105-118.  show abstract

Ascierto, P.A. Grimaldi, A.M. Acquavella, N. Borgognoni, L. Calabro, L. Cascinelli, N. Cesano, A. Del Vecchio, M. Eggermont, A.M. Faries, M. Ferrone, S. Fox, B.A. Gajewski, T.F. Galon, J. Gnjatic, S. Gogas, H. Kashani-Sabet, M. Kaufman, H.L. Larkin, J. Lo, R.S. Mantovani, A. Margolin, K. Melief, C. McArthur, G. Palmieri, G. Puzanov, I. Ribas, A. Seliger, B. Sosman, J. Suenaert, P. Tarhini, A.A. Trinchieri, G. Vidal-Vanaclocha, F. Wang, E. Ciliberto, G. Mozzillo, N. Marincola, F.M. Thurin, M. (2013). Future perspectives in melanoma research Meeting report from the "Melanoma Bridge Napoli, December 2nd-4th 2012". Journal of translational medicine, Vol.11.

Fearfield, L. Newton-Bishop, J.A. Sinha, R. Edmonds, K. Gore, M.E. Larkin, J. (2013). Second primary melanomas on treatment with vemurafenib: reply from the authors. Br j dermatol, Vol.168 (4), pp. 888-889.

Turajlic, S. Ali, Z. Yousaf, N. Larkin, J. (2013). Phase I/II RAF kinase inhibitors in cancer therapy. Expert opin investig drugs, Vol.22 (6), pp. 739-749.  show abstract

Furney, S.J. Turajlic, S. Stamp, G. Nohadani, M. Carlisle, A. Thomas, J.M. Hayes, A. Strauss, D. Gore, M. van den Oord, J. Larkin, J. Marais, R. (2013). Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J pathol, Vol.230 (3), pp. 261-269.  show abstract

Martinez, P. Birkbak, N.J. Gerlinger, M. McGranahan, N. Burrell, R.A. Rowan, A.J. Joshi, T. Fisher, R. Larkin, J. Szallasi, Z. Swanton, C. (2013). Parallel evolution of tumour subclones mimics diversity between tumours. J pathol, Vol.230 (4), pp. 356-364.  show abstract

Fisher, R. Larkin, J. (2013). Individualising treatment choices in a crowded treatment algorithm. European journal of cancer supplements, Vol.11 (2), pp. 160-168.

Ali, Z. Yousaf, N. Larkin, J. (2013). Melanoma epidemiology, biology and prognosis. European journal of cancer supplements, Vol.11 (2), pp. 81-91.

Gerlinger, M. Quezada, S.A. Peggs, K.S. Furness, A.J. Fisher, R. Marafioti, T. Shende, V.H. McGranahan, N. Rowan, A.J. Hazell, S. Hamm, D. Robins, H.S. Pickering, L. Gore, M. Nicol, D.L. Larkin, J. Swanton, C. (2013). Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. J pathol, Vol.231 (4), pp. 424-432.  show abstract

Yousaf, N. Larkin, J. (2013). Axitinib in advanced renal-cell carcinoma. Lancet oncol, Vol.14 (13), pp. 1245-1246.

Henrion, M. Frampton, M. Scelo, G. Purdue, M. Ye, Y. Broderick, P. Ritchie, A. Kaplan, R. Meade, A. McKay, J. Johansson, M. Lathrop, M. Larkin, J. Rothman, N. Wang, Z. Chow, W.-. Stevens, V.L. Ryan Diver, W. Gapstur, S.M. Albanes, D. Virtamo, J. Wu, X. Brennan, P. Chanock, S. Eisen, T. Houlston, R.S. (2013). Common variation at 2q22 3 (ZEB2) influences the risk of renal cancer. Hum mol genet, Vol.22 (4), pp. 825-831.  show abstract

Vasudev, N.S. Goh, V. Juttla, J.K. Thompson, V.L. Larkin, J.M. Gore, M. Nathan, P.D. Reynolds, A.R. (2013). Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. British journal of cancer, Vol.109 (5).

Karapanagiotou, E.M. Roulstone, V. Twigger, K. Ball, M. Tanay, M. Nutting, C. Newbold, K. Gore, M.E. Larkin, J. Syrigos, K.N. Coffey, M. Thompson, B. Mettinger, K. Vile, R.G. Pandha, H.S. Hall, G.D. Melcher, A.A. Chester, J. Harrington, K.J. (2012). Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin cancer res, Vol.18 (7), pp. 2080-2089.  show abstract

Pacey, S. Gore, M. Chao, D. Banerji, U. Larkin, J. Sarker, S. Owen, K. Asad, Y. Raynaud, F. Walton, M. Judson, I. Workman, P. Eisen, T. (2012). A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest new drugs, Vol.30 (1), pp. 341-349.  show abstract

Fisher, R. Cahalin, P. Gore, M. Larkin, J. (2012). A tale of two tumours and a plea for progress. Lancet oncol, Vol.13 (2), pp. 124-125.

Turajlic, S. Furney, S.J. Lambros, M.B. Mitsopoulos, C. Kozarewa, I. Geyer, F.C. Mackay, A. Hakas, J. Zvelebil, M. Lord, C.J. Ashworth, A. Thomas, M. Stamp, G. Larkin, J. Reis-Filho, J.S. Marais, R. (2012). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome res, Vol.22 (2), pp. 196-207.  show abstract

Gruenwald, V. Karakiewicz, P.I. Bavbek, S.E. Miller, K. Machiels, J.-. Lee, S.-. Larkin, J. Bono, P. Rha, S.Y. Castellano, D. Blank, C.U. Knox, J.J. Hawkins, R. Anak, O. Rosamilia, M. Booth, J. Pirotta, N. Bodrogi, I. Grp, R.E. (2012). An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. European journal of cancer, Vol.48 (3), pp. 324-332.

Fisher, R. Larkin, J. (2012). Treatment of brain metastases in patients with melanoma. Lancet oncol, Vol.13 (5), pp. 434-435.

Young, K. Minchom, A. Larkin, J. (2012). BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future oncol, Vol.8 (5), pp. 499-507.  show abstract

Gerlinger, M. Santos, C.R. Spencer-Dene, B. Martinez, P. Endesfelder, D. Burrell, R.A. Vetter, M. Jiang, M. Saunders, R.E. Kelly, G. Dykema, K. Rioux-Leclercq, N. Stamp, G. Patard, J.J. Larkin, J. Howell, M. Swanton, C. (2012). Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J pathol, Vol.227 (2), pp. 146-156.  show abstract

Larkin, J. Esser, N. Calvo, E. Tsuchihashi, Z. Fiedler, U. Graeser, R. Kim, D. (2012). Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma. Anticancer res, Vol.32 (7), pp. 2399-2406.  show abstract

Gerlinger, M. Rowan, A.J. Horswell, S. Math, M. Larkin, J. Endesfelder, D. Gronroos, E. Martinez, P. Matthews, N. Stewart, A. Tarpey, P. Varela, I. Phillimore, B. Begum, S. McDonald, N.Q. Butler, A. Jones, D. Raine, K. Latimer, C. Santos, C.R. Nohadani, M. Eklund, A.C. Spencer-Dene, B. Clark, G. Pickering, L. Stamp, G. Gore, M. Szallasi, Z. Downward, J. Futreal, P.A. Swanton, C. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N engl j med, Vol.366 (10), pp. 883-892.  show abstract

Khattak, M. Gore, M. Larkin, J. Strauss, D. Thomas, M. Hayes, A. Harrington, K. (2012). Adjuvant nodal irradiation in melanoma. Lancet oncol, Vol.13 (8), pp. e326-e327.

Larkin, J.M. Fisher, R.A. Gore, M.E. (2012). Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review. Clinical oncology, Vol.24 (6), pp. 410-412.

Thway, K. du Parcq, J. Larkin, J.M. Fisher, C. Livni, N. (2012). Metastatic renal mucinous tubular and spindle cell carcinoma Atypical behavior of a rare, morphologically bland tumor. Ann diagn pathol, Vol.16 (5), pp. 407-410.  show abstract

Larkin, J.M. Blank, C.U. Bono, P. Gogov, S. Panneerselvam, A. Garay, C.A. Grünwald, V. REACT Study Group, (2012). Everolimus in patients with metastatic renal cell carcinoma refractory to VEGF-targeted therapy: REACT subgroup analysis of prior therapy. J clin oncol, Vol.30 (5_suppl), p. 391.  show abstract

Blank, C.U. Bono, P. Larkin, J.M. Gogov, S. Panneerselvam, A. Garay, C.A. Grünwald, V. REACT Study Group, (2012). Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: Subgroup analysis of REACT. J clin oncol, Vol.30 (5_suppl), p. 402.  show abstract

Larkin, J.M. Blank, C.U. Bono, P. Gogov, S. Panneerselvam, A. Garay, C.A. Gruenwald, V. Grp, R.E. (2012). Everolimus in patients with metastatic renal cell carcinoma refractory to VEGF-targeted therapy: REACT subgroup analysis of prior therapy. Journal of clinical oncology, Vol.30 (5).

Blank, C.U. Bono, P. Larkin, J.M. Gogov, S. Panneerselvam, A. Garay, C.A. Gruenwald, V. Grp, R.E. (2012). Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: Subgroup analysis of REACT. Journal of clinical oncology, Vol.30 (5).

Khattak, M.A. Fisher, R.A. Pickering, L.M. Gore, M.E. Larkin, J.M. (2012). Endobronchial metastases from renal cell carcinoma: a late manifestation of the disease with an increasing incidence. Bju int, Vol.110 (10), pp. 1407-1408.

Sinha, R. Edmonds, K. Newton-Bishop, J.A. Gore, M.E. Larkin, J. Fearfield, L. (2012). Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br j dermatol, Vol.167 (5), pp. 987-994.  show abstract

Proskorovsky, I. Benedict, A. Larkin, J.M. Sandin, R. Chen, C. (2012). AXITINIB (AXI) AND BEST SUPPORTIVE CARE (BSC) IN THE TREATMENT OF SUNITINIB-REFRACTORY PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS OF A SIMULATED TREATMENT COMPARISON (STC) ANALYSES. Value in health, Vol.15 (7), pp. A410-A410.

Flaherty, K.T. Robert, C. Hersey, P. Nathan, P. Garbe, C. Milhem, M. Demidov, L.V. Hassel, J.C. Rutkowski, P. Mohr, P. Dummer, R. Trefzer, U. Larkin, J.M. Utikal, J. Dreno, B. Nyakas, M. Middleton, M.R. Becker, J.C. Casey, M. Sherman, L.J. Wu, F.S. Ouellet, D. Martin, A.-. Patel, K. Schadendorf, D. Grp, M.E. (2012). Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New england journal of medicine, Vol.367 (2), pp. 107-114.

Gerlinger, M. Rowan, A. Horswell, S. Larkin, J. Endesfelder, D. Gronroos, E. Martinez, P. Matthews, N. Stewart, A. Tarpey, P. Varela, I. Phillimore, B. Begum, S. McDonald, N. Butler, A. Jones, D. Raine, K. Latimer, C. Santos, C. Nohadani, M. Eklund, A. Spencer-Dene, B. Clark, G. Pickering, L. Stamp, G. Gore, M. Szallasi, Z. Downward, J. Futreal, P.A. Swanton, C. (2012). Abstract 964: Intra-tumor heterogeneity and Darwinian selection revealed by multi-region exome sequencing of renal cell carcinomas. Cancer research, Vol.72 (8_Supplement), pp. 964-964.  show abstract

Kirkwood, J.M. Bastholt, L. Robert, C. Sosman, J. Larkin, J. Hersey, P. Middleton, M. Cantarini, M. Zazulina, V. Kemsley, K. Dummer, R. (2012). Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma. Clinical cancer research, Vol.18 (2), pp. 555-567.

Larkin, J. Goh, X.Y. Vetter, M. Pickering, L. Swanton, C. (2012). Epigenetic regulation in RCC: opportunities for therapeutic intervention?. Nat rev urol, Vol.9 (3), pp. 147-155.  show abstract

Swanton, C. Larkin, J. Gerlinger, M. (2012). Intratumor Heterogeneity and Branched Evolution REPLY. New england journal of medicine, Vol.366 (22), pp. 2133-2133.

Fisher, R. Pender, A. Thillai, K. Chowdhury, S. Pickering, L. Khabra, K. Gore, M. Larkin, J. (2012). Observation as a treatment strategy for advanced renal cell carcinoma-a call for prospective validation. Front oncol, Vol.2, p. 155.

Fisher, R. Larkin, J. (2012). Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer manag res, Vol.4, pp. 243-252.  show abstract

Fisher, R. Larkin, J. Swanton, C. (2012). Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma?. Front oncol, Vol.2, p. 49.

Suwaki, N. Vanhecke, E. Atkins, K.M. Graf, M. Swabey, K. Huang, P. Schraml, P. Moch, H. Cassidy, A.M. Brewer, D. Al-Lazikani, B. Workman, P. De-Bono, J. Kaye, S.B. Larkin, J. Gore, M.E. Sawyers, C.L. Nelson, P. Beer, T.M. Geng, H. Gao, L. Qian, D.Z. Alumkal, J.J. Thomas, G. Thomas, G.V. (2011). A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci transl med, Vol.3 (85), p. 85ra47.  show abstract

Gore, M.E. Larkin, J.M. (2011). Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. British journal of cancer, Vol.104 (3), pp. 399-406.

Khan, O.A. Gore, M. Lorigan, P. Stone, J. Greystoke, A. Burke, W. Carmichael, J. Watson, A.J. McGown, G. Thorncroft, M. Margison, G.P. Califano, R. Larkin, J. Wellman, S. Middleton, M.R. (2011). A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. British journal of cancer, Vol.104 (5), pp. 750-755.

Okera, M. Chan, S. Dernede, U. Larkin, J. Popat, S. Gilbert, D. Jones, L. Osuji, N. Sykes, H. Oakley, C. Pickering, L. Lofts, F. Chowdhury, S. (2011). A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network Interpretation of study results in light of NCAG/NCEPOD findings. British journal of cancer, Vol.104 (3), pp. 407-412.

Larkin, J. Swanton, C. Pickering, L. (2011). Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert rev anticancer ther, Vol.11 (4), pp. 639-649.  show abstract

Bex, A. Larkin, J. Blank, C. (2011). Non-Clear Cell Renal Cell Carcinoma: How New Biological Insight May Lead to New Therapeutic Modalities. Current oncology reports, Vol.13 (3), pp. 240-248.

Fisher, R. Pickering, L. Larkin, J. (2011). New targeted therapies for renal cell carcinoma. Expert opin investig drugs, Vol.20 (7), pp. 933-945.  show abstract

Josephs, D. Hutson, T.E. Cowey, C.L. Pickering, L.M. Larkin, J.M. Gore, M.E. Van Hemelrijck, M. McDermott, D.F. Powles, T. Chowdhury, P. Karapetis, C. Harper, P.G. Choueiri, T.K. Chowdhury, S. (2011). Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. Bju international, Vol.108 (8), pp. 1279-1283.

Larkin, J.M. Gore, M.E. (2011). Primary Excision Margins and Sentinel Lymph Node Biopsy in Clinically Node-negative Melanoma of the Trunk or Extremities. Clinical oncology, Vol.23 (9), pp. 569-571.

Minchom, A. Young, K. Larkin, J. (2011). Ipilimumab: showing survival benefit in metastatic melanoma. Future oncol, Vol.7 (11), pp. 1255-1264.  show abstract

Sanz-Moreno, V. Gaggioli, C. Yeo, M. Albrengues, J. Wallberg, F. Viros, A. Hooper, S. Mitter, R. Féral, C.C. Cook, M. Larkin, J. Marais, R. Meneguzzi, G. Sahai, E. Marshall, C.J. (2011). ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer cell, Vol.20 (2), pp. 229-245.  show abstract

Larkin, J.M. Fisher, R.A. Pickering, L.M. Sohaib, S.A. Ghosn, M. Christmas, T. Cordiner, R.L. Gore, M.E. (2011). Chromophobe Renal Cell Carcinoma With Prolonged Response to Sequential Sunitinib and Everolimus. Journal of clinical oncology, Vol.29 (9), pp. E241-E242.

Ratnayake, G. Pender, A. Pickering, L.M. Gore, M.E. Larkin, J.M. (2011). Intrapatient correlation of clinical benefit from VEGF and mTOR inhibition in metastatic renal cell carcinoma. Journal of clinical oncology, Vol.29 (15).

Hutson, T.E. Bukowski, R.M. Rini, B.I. Gore, M.E. Larkin, J.M. Figlin, R.A. Barrios, C.H. Escudier, B. Lin, X. Fly, K.D. Martell, B. Matczak, E. Motzer, R.J. (2011). A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of clinical oncology, Vol.29 (15).

Leary, A. Pickering, L.M. Larkin, J.M. Leach, M.O. Gore, M.E. Sohaib, A. Collins, D.J. Koh, D. (2011). Quantitative diffusion-weighted (DW) MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma (RCC) to treatment with sunitinib. Journal of clinical oncology, Vol.29 (15).

Fisher, R.A. Pender, A. Thillai, K. Chowdhury, S. Pickering, L.M. Rose, S.S. Gore, M.E. Larkin, J.M. (2011). Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era. Journal of clinical oncology, Vol.29 (15).

Chapman, P.B. Hauschild, A. Robert, C. Larkin, J.M. Haanen, J.B. Ribas, A. Hogg, D. O'Day, S. Ascierto, P.A. Testori, A. Lorigan, P. Dummer, R. Sosman, J.A. Garbe, C. Lee, R.J. Nolop, K.B. Nelson, B. Hou, J. Flaherty, K.T. McArthur, G.A. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with (V600E)BRAF-mutated melanoma. J clin oncol, Vol.29 (18_suppl), p. LBA4.  show abstract

Hutson, T.E. Bukowski, R.M. Rini, B.I. Gore, M.E. Larkin, J.M. Figlin, R.A. Barrios, C.H. Escudier, B. Lin, X. Fly, K.D. Martell, B. Matczak, E. Motzer, R.J. (2011). A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). J clin oncol, Vol.29 (15_suppl), p. 4604.  show abstract

Fisher, R.A. Pender, A. Thillai, K. Chowdhury, S. Pickering, L.M. St Rose, S. Gore, M.E. Larkin, J.M. (2011). Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era. J clin oncol, Vol.29 (15_suppl), p. 4630.  show abstract

Larkin, J.M. Turajlic, S. Nathan, P.D. Lorigan, P. Stamp, G. Gonzalez de Castro, D. Martin, N. Griffiths, J. Edmonds, K. Sarker, S. James, M.G. A'Hern, R. Coombes, G. Snowdon, C. Bliss, J.M. Gore, M.E. Marais, R. (2011). A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM). J clin oncol, Vol.29 (15_suppl), p. TPS229.  show abstract

Leary, A. Pickering, L.M. Larkin, J.M. Leach, M.O. Gore, M.E. Sohaib, A. Collins, D.J. Koh, D. (2011). Quantitative diffusion-weighted (DW) MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma (RCC) to treatment with sunitinib. J clin oncol, Vol.29 (15_suppl), p. TPS154.  show abstract

Ratnayake, G. Pender, A. Pickering, L.M. Gore, M.E. Larkin, J.M. (2011). Intrapatient correlation of clinical benefit from VEGF and mTOR inhibition in metastatic renal cell carcinoma. J clin oncol, Vol.29 (15_suppl), p. e15175.  show abstract

Chapman, P.B. Hauschild, A. Robert, C. Larkin, J.M. Haanen, J.B. Ribas, A. Hogg, D. O'Day, S. Ascierto, P.A. Testori, A. Lorigan, P. Dummer, R. Sosman, J.A. Garbe, C. Lee, R.J. Nolop, K.B. Nelson, B. Hou, J. Flaherty, K.T. McArthur, G.A. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. J clin oncol, Vol.29 (15_suppl), p. LBA4.  show abstract

Grünwald, V. Karakiewicz, P.I. Bavbek, S.E. Miller, K. Machiels, J.H. Lee, S. Larkin, J.M. Bono, P. Rha, S.Y. Castellano, D.E. Blank, C.U. Knox, J.J. Hawkins, R. Yuan, R.R. Rosamilia, M. Booth, J.L. Bodrogi, I. REACT Study Group, (2011). Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. J clin oncol, Vol.29 (15_suppl), p. 4601.  show abstract

Gruenwald, V. Karakiewicz, P.I. Bavbek, S.E. Miller, K. Machiels, J.H. Lee, S. Larkin, J.M. Bono, P. Rha, S.Y. Castellano, D.E. Blank, C.U. Knox, J.J. Hawkins, R. Yuan, R.R. Rosamilia, M. Booth, J.L. Bodrogi, I. Grp, R.E. (2011). Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. Journal of clinical oncology, Vol.29 (15).

Chapman, P.B. Hauschild, A. Robert, C. Larkin, J.M. Haanen, J.B. Ribas, A. Hogg, D. O'Day, S. Ascierto, P.A. Testori, A. Lorigan, P. Dummer, R. Sosman, J.A. Garbe, C. Lee, R.J. Nolop, K.B. Nelson, B. Hou, J. Flaherty, K.T. McArthur, G.A. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. Journal of clinical oncology, Vol.29 (15).

Chapman, P.B. Hauschild, A. Robert, C. Larkin, J.M. Haanen, J.B. Ribas, A. Hogg, D. O'Day, S. Ascierto, P.A. Testori, A. Lorigan, P. Dummer, R. Sosman, J.A. Garbe, C. Lee, R.J. Nolop, K.B. Nelson, B. Hou, J. Flaherty, K.T. McArthur, G.A. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with (V600E)BRAF-mutated melanoma. Journal of clinical oncology, Vol.29 (18).

Chapman, P.B. Hauschild, A. Robert, C. Haanen, J.B. Ascierto, P. Larkin, J. Dummer, R. Garbe, C. Testori, A. Maio, M. Hogg, D. Lorigan, P. Lebbe, C. Jouary, T. Schadendorf, D. Ribas, A. O'Day, S.J. Sosman, J.A. Kirkwood, J.M. Eggermont, A.M. Dreno, B. Nolop, K. Li, J. Nelson, B. Hou, J. Lee, R.J. Flaherty, K.T. McArthur, G.A. Grp, B.S. (2011). Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New england journal of medicine, Vol.364 (26), pp. 2507-2516.

Fisher, R. Larkin, J. (2011). Renal cell cancer: what can we learn from pre-operative studies?. Front oncol, Vol.1, p. 51.

Larkin, J. Fisher, R. Pickering, L. Thway, K. Livni, N. Fisher, C. Gore, M. (2010). Metastatic Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Responding to Sunitinib. Journal of clinical oncology, Vol.28 (28), pp. E539-2.

Rennalls, L.P. Seidl, T. Larkin, J.M. Wellbrock, C. Gore, M.E. Eisen, T. Bruno, L. (2010). The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells. Immunology, Vol.129 (4), pp. 610-619.

Mukherji, D. Larkin, J. Pickering, L. (2010). Sunitinib for metastatic renal cell carcinoma. Future oncology, Vol.6 (9), pp. 1377-1385.

Goldstein, R. Pickering, L. Larkin, J. (2010). Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?. Expert review of anticancer therapy, Vol.10 (10), pp. 1545-1557.

Larkin, J.M. Ferguson, T.R. Pickering, L.M. Edmonds, K. James, M.G. Thomas, K. Banerji, U. Berns, B. de Boer, C. Gore, M.E. (2010). A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br j cancer, Vol.103 (8), pp. 1149-1153.  show abstract

Pickering, L.M. Constantinidou, A. Larkin, J.M. Sohaib, S.A. Khatri, P. Nathan, P.D. Vinayan, A. Ferguson, T. St Rose, S. Gore, M.E. (2010). Sunitinib treatment for longer than 2 years for renal cell carcinoma. Journal of clinical oncology, Vol.28 (15).

Larkin, J.M. Hess, V. Pickering, L.M. Ferguson, T. Forrest, R. Gore, M.E. (2010). Symptomatic brain metastases from renal cell carcinoma during treatment with sunitinib or sorafenib. Journal of clinical oncology, Vol.28 (15).

Swanton, C. Juul, N. Larkin, J.M. Eklund, A. Li, Q. Desmedt, C. Sotiriou, C. Pusztal, L. Szallasi, Z. (2010). Use of an RNA interference screen-derived mitotic and ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer. Journal of clinical oncology, Vol.28 (15).

Larkin, J. Gore, M. (2010). Is advanced renal cell carcinoma becoming a chronic disease?. Lancet, Vol.376 (9741), pp. 574-575.

Fisher, R.A. Larkin, J. (2010). Malignant melanoma (metastatic). Bmj clin evid, Vol.2010.  show abstract

Larkin, J.M. Pyle, L.M. Gore, M.E. (2010). Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies. Oncologist, Vol.15 (11), pp. 1135-1146.  show abstract

Swanton, C. Larkin, J.M. Gerlinger, M. Eklund, A.C. Howell, M. Stamp, G. Downward, J. Gore, M. Futreal, P.A. Escudier, B. Andre, F. Albiges, L. Beuselinck, B. Oudard, S. Hoffmann, J. Gyorffy, B. Torrance, C.J. Boehme, K.A. Volkmer, H. Toschi, L. Nicke, B. Beck, M. Szallasi, Z. (2010). Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome medicine, Vol.2.

Pickering, L.M. Pyle, L. Larkin, J.M. (2009). Sunitinib is superior to interferon alpha with respect to quality of life for patients with renal cell carcinoma. Nat clin pract oncol, Vol.6 (1), pp. 6-7.  show abstract

Larkin, J.M. Clarke, R.E. Pickering, L.M. (2009). Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: biology and pathways. Medical oncology, Vol.26, pp. 40-45.

Larkin, J.M. Kipps, E.L. Powell, C.J. Swanton, C. (2009). Systemic therapy for advanced renal cell carcinoma. Ther adv med oncol, Vol.1 (1), pp. 15-27.  show abstract

Sternberg, C.N. Bellmunt, J. Gruenwald, V. Larkin, J. Mulders, P. (2009). Advances in the Management of Metastatic Renal Cell Cancer. European urology supplements, Vol.8 (9), pp. 758-761.

Larkin, J. Gore, M. (2009). HEALTH POLICY The UK 'postcode lottery' in renal cell carcinoma. Nature reviews urology, Vol.6 (12), pp. 636-638.

Miller, R.E. Larkin, J.M. (2009). Combination systemic therapy for advanced renal cell carcinoma. Oncologist, Vol.14 (12), pp. 1218-1224.  show abstract

Josephs, D.H. Hutson, T.E. Pickering, L.M. Larkin, J.M. Choueiri, T.K. Patel, T.V. Mcdermott, D.F. Powles, T. Harper, P.G. Chowdhury, S. (2009). Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis. J clin oncol, Vol.27 (15_suppl), p. 5109.  show abstract

Carden, C.P. Myerson, J.S. Popat, S. Montes, A. Larkin, J.M. Benson, M.J. O'Brien, M.E. (2008). Good vibrations and the power of positron thinking: positron emission tomography and endoscopic ultrasound in staging of mesothelioma-two case reports. J thorac oncol, Vol.3 (5), pp. 539-541.

Carden, C.P. Larkin, J.M. Rosenthal, M.A. (2008). What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro oncol, Vol.10 (4), pp. 624-630.  show abstract

Chowdhury, S. Larkin, J.M. Gore, M.E. (2008). Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. European journal of cancer, Vol.44 (15), pp. 2152-2161.

Dernedde, U. Chan, S. Sykes, H. Oakley, C. Larkin, J. Popat, S. Gilbert, D. Jones, L. Chowdhury, S. (2008). South West London Cancer Network (SWLCN) audit of patients with chemotherapy-induced febrile neutropenia (CIFN). Journal of clinical oncology, Vol.26 (15).

Larkin, J. Gore, M. (2008). Malignant melanoma (metastatic). Bmj clin evid, Vol.2008.  show abstract

Fearfield, L.A. Larkin, J.M. Rowe, A. A'Hern, R. Fisher, C. Francis, N. MacKie, R. McCann, B. Gore, M.E. Bunker, C.B. (2007). Expression of p16, CD95, CD95L and Helix pomatia agglutinin in relapsing and nonrelapsing very thin melanoma. British journal of dermatology, Vol.156 (3), pp. 440-8.

Larkin, J.M. Porter, C.D. (2007). Complement insufficiency limits efficacy in a xenograft model of hyperacute rejection for cancer therapy. Cancer immunology immunotherapy, Vol.56 (1), pp. 60-69.

Larkin, J.M. (2007). Patupilone Antimitotic drug, microtubule-stabilizing agent, oncolytic. Drugs of the future, Vol.32 (4), pp. 323-336.

Larkin, J.M. Kaye, S.B. (2007). Potential clinical applications of epothilones: a review of phase II studies. Ann oncol, Vol.18 Suppl 5, pp. v28-v34.  show abstract

Larkin, J.M. Chowdhury, S. Gore, M.E. (2007). Drug insight: advances in renal cell carcinoma and the role of targeted therapies. Nat clin pract oncol, Vol.4 (8), pp. 470-479.  show abstract

Larkin, J.M. Hughes, S.A. Beirne, D.A. Patel, P.M. Gibbens, I.M. Bate, S.C. Thomas, K. Eisen, T.G. Gore, M.E. (2007). A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. British journal of cancer, Vol.96 (1), pp. 44-48.

Larkin, J.M. Kaye, S.B. (2006). Epothilones in the treatment of cancer. Expert opinion on investigational drugs, Vol.15 (6), pp. 691-12.

Larkin, J.M. Norsworth, P.J. A'Hern, R.P. Eisen, T.G. Gore, M.E. Porter, C.D. (2006). Anti-alpha Gal-dependent complement-mediated cytotoxicity in metastatic melanoma. Melanoma research, Vol.16 (2), pp. 157-7.

Larkin, J.M. Eisen, T. (2006). Renal cell carcinoma and the use of sorafenib. Ther clin risk manag, Vol.2 (1), pp. 87-98.  show abstract

Larkin, J.M. Eisen, T. (2006). Kinase inhibitors in the treatment of renal cell carcinoma. Crit rev oncol hematol, Vol.60 (3), pp. 216-226.  show abstract

Larkin, J.M. Porter, C.D. (2005). Mice are unsuitable for modelling ABO discordance despite strain-specific A cross-reactive natural IgM. British journal of haematology, Vol.130 (2), pp. 310-317.

Larkin, J.M. Gore, M.E. (2005). The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): Rationale and progress. Clinical oncology, Vol.17 (5), pp. 319-321.

Kolomainen, D.F. Larkin, J.M. Badran, M. A'Hern, R.P. King, D.M. Fisher, C. Bridges, J.E. Blake, P.R. Barton, D.P. Shepherd, J.H. Kaye, S.B. Gore, M.E. (2002). Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J clin oncol, Vol.20 (4), pp. 982-986.  show abstract

Kolomainen, D.F. Larkin, J.M. Badran, M. A’Hern, R.P. King, D.M. Fisher, C. Bridges, J.E. Blake, P.R. Barton, D.P. Shepherd, J.H. Kaye, S.B. Gore, M.E. (2002). Epithelial Ovarian Cancer Metastasizing to the Brain: A Late Manifestation of the Disease With an Increasing Incidence. Journal of clinical oncology, Vol.20 (4), pp. 982-986.  show abstract

Gulati, S. Martinez, P. Joshi, T. Birbak, N.J. Santos, C.R. Rowan, A.J. Pickering, L. Gore, M. Larkin, J. Szallasi, Z. Bates, P.A. Swanton, C. Gerlinger, M. Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. European urology, .  show abstract

Henrion, M.Y. Purdue, M.P. Scelo, G. Broderick, P. Frampton, M. Ritchie, A. Meade, A. Li, P. McKay, J. Johansson, M. Lathrop, M. Larkin, J. Rothman, N. Wang, Z. Chow, W.-. Stevens, V.L. Diver, W.R. Albanes, D. Virtamo, J. Brennan, P. Eisen, T. Chanock, S. Houlston, R.S. Common Variation at 1q24 1 (ALDH9A1) Is a Potential Risk Factor for Renal Cancer. Plos one, Vol.10 (3), pp. e0122589-e0122589.

Biondo, A. Alexander, H. Khabra, K. Pickering, L. Gore, M. Larkin, J. Pazopanib-Induced Alopecia, an Underestimated Toxicity?. Frontiers in oncology, Vol.5.

Eggermont, A.M. Blank, C.U. Mandala, M. Long, G.V. Atkinson, V. Dalle, S. Haydon, A. Lichinitser, M. Khattak, A. Carlino, M.S. Sandhu, S. Larkin, J. Puig, S. Ascierto, P.A. Rutkowski, P. Schadendorf, D. Koornstra, R. Hernandez-Aya, L. Maio, M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. Lorigan, P. Ibrahim, N. Marreaud, S. van Akkooi, A.C. Suciu, S. Robert, C. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. The new england journal of medicine, Vol.378 (19), pp. 1789-1801.  show abstract

Argyropulo-Palmer, M. Jenkins, A. Theti, D.S. Larkin, J. Montgomery, D. Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data. Frontiers in oncology, Vol.5.

Larkin, J. Hatswell, A.J. Nathan, P. Lebmeier, M. Lee, D. The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK. Plos one, Vol.10 (12), pp. e0145524-e0145524.

Wolchok, J.D. Chiarion-Sileni, V. Gonzalez, R. Grob, J.-. Rutkowski, P. Lao, C.D. Cowey, C.L. Schadendorf, D. Wagstaff, J. Dummer, R. Ferrucci, P.F. Smylie, M. Butler, M.O. Hill, A. Márquez-Rodas, I. Haanen, J.B. Guidoboni, M. Maio, M. Schöffski, P. Carlino, M.S. Lebbé, C. McArthur, G. Ascierto, P.A. Daniels, G.A. Long, G.V. Bas, T. Ritchings, C. Larkin, J. Hodi, F.S. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of clinical oncology : official journal of the american society of clinical oncology, Vol.40 (2), pp. 127-137.  show abstract

Fendler, A. Au, L. Shepherd, S.T. Byrne, F. Cerrone, M. Boos, L.A. Rzeniewicz, K. Gordon, W. Shum, B. Gerard, C.L. Ward, B. Xie, W. Schmitt, A.M. Joharatnam-Hogan, N. Cornish, G.H. Pule, M. Mekkaoui, L. Ng, K.W. Carlyle, E. Edmonds, K. Rosario, L.D. Sarker, S. Lingard, K. Mangwende, M. Holt, L. Ahmod, H. Stone, R. Gomes, C. Flynn, H.R. Agua-Doce, A. Hobson, P. Caidan, S. Howell, M. Wu, M. Goldstone, R. Crawford, M. Cubitt, L. Patel, H. Gavrielides, M. Nye, E. Snijders, A.P. MacRae, J.I. Nicod, J. Gronthoud, F. Shea, R.L. Messiou, C. Cunningham, D. Chau, I. Starling, N. Turner, N. Welsh, L. van As, N. Jones, R.L. Droney, J. Banerjee, S. Tatham, K.C. Jhanji, S. O’Brien, M. Curtis, O. Harrington, K. Bhide, S. Bazin, J. Robinson, A. Stephenson, C. Slattery, T. Khan, Y. Tippu, Z. Leslie, I. Gennatas, S. Okines, A. Reid, A. Young, K. Furness, A.J. Pickering, L. Gandhi, S. Gamblin, S. Swanton, C. Nicholson, E. Kumar, S. Yousaf, N. Wilkinson, K.A. Swerdlow, A. Harvey, R. Kassiotis, G. Larkin, J. Wilkinson, R.J. Turajlic, S. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature cancer, Vol.2 (12), pp. 1321-1337.  show abstract

Lidington, E. Darlington, A.S. Vlooswijk, C. Beardsworth, S. McCaffrey, S. Tang, S. Stallard, K. Younger, E. Edwards, P. Ali, A.I. Nandhabalan, M. Din, A. Starling, N. Larkin, J. Stanway, S. Nobbenhuis, M. Banerjee, S. Szucs, Z. Gonzalez, M. Sirohi, B. Husson, O. van der Graaf, W.T. Beyond Teenage and Young Adult Cancer Care: Care Experiences of Patients Aged 25-39 Years Old in the UK National Health Service. Clinical oncology (royal college of radiologists (great britain)), Vol.33 (8), pp. 494-506.  show abstract

Alexander, J.L. Ibraheim, H. Sheth, B. Little, J. Khan, M.S. Richards, C. Hunter, N. Chauhan, D. Ratnakumaran, R. McHugh, K. Pinato, D.J. Nathan, P. Choy, J. Crusz, S.M. Furness, A. Turajlic, S. Pickering, L. Larkin, J. Teare, J.P. Papa, S. Speight, A. Sharma, A. Powell, N. Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. Journal for immunotherapy of cancer, Vol.9 (7).  show abstract

Au, L. Hatipoglu, E. Robert de Massy, M. Litchfield, K. Beattie, G. Rowan, A. Schnidrig, D. Thompson, R. Byrne, F. Horswell, S. Fotiadis, N. Hazell, S. Nicol, D. Shepherd, S.T. Fendler, A. Mason, R. Del Rosario, L. Edmonds, K. Lingard, K. Sarker, S. Mangwende, M. Carlyle, E. Attig, J. Joshi, K. Uddin, I. Becker, P.D. Sunderland, M.W. Akarca, A. Puccio, I. Yang, W.W. Lund, T. Dhillon, K. Vasquez, M.D. Ghorani, E. Xu, H. Spencer, C. López, J.I. Green, A. Mahadeva, U. Borg, E. Mitchison, M. Moore, D.A. Proctor, I. Falzon, M. Pickering, L. Furness, A.J. Reading, J.L. Salgado, R. Marafioti, T. Jamal-Hanjani, M. PEACE Consortium, Kassiotis, G. Chain, B. Larkin, J. Swanton, C. Quezada, S.A. Turajlic, S. TRACERx Renal Consortium, Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer cell, Vol.39 (11), pp. 1497-1518.e11.  show abstract

Fu, X. Zhao, Y. Lopez, J.I. Rowan, A. Au, L. Fendler, A. Hazell, S. Xu, H. Horswell, S. Shepherd, S.T. Spencer, C.E. Spain, L. Byrne, F. Stamp, G. O'Brien, T. Nicol, D. Augustine, M. Chandra, A. Rudman, S. Toncheva, A. Furness, A.J. Pickering, L. Kumar, S. Koh, D.-. Messiou, C. Dafydd, D.A. Orton, M.R. Doran, S.J. Larkin, J. Swanton, C. Sahai, E. Litchfield, K. Turajlic, S. TRACERx Renal Consortium, Bates, P.A. Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. Nature ecology & evolution, Vol.6 (1), pp. 88-102.  show abstract

Gudd, C.L. Au, L. Triantafyllou, E. Shum, B. Liu, T. Nathwani, R. Kumar, N. Mukherjee, S. Dhar, A. Woollard, K.J. Yone, Y. Pinato, D.J. Thursz, M.R. Goldin, R.D. Gore, M.E. Larkin, J. Khamri, W. Antoniades, C.G. Turajlic, S. Possamai, L.A. Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. Journal of hepatology, Vol.75 (1), pp. 177-189.  show abstract


Book Chapters

Spain, L. Postow, M.A. Larkin, J. Weber, J. (2019). Indications and Toxicities of Immune Checkpoint Inhibitor Combinations. SITC’s Guide to Managing Immunotherapy Toxicity. Springer Publishing Company.


Conferences

Hirata, E.Girotti, M.R.Viros, A.Hooper, S.Spencer-Dene, B.Matsuda, M.Larkin, J.Marais, R.Sahai, E. (2015). Intravital imaging reveals how BRaf inhibition generates drug tolerant microenvironments., JOURNAL OF NUCLEAR MEDICINE, Vol.56 (2), p.26.

Ribas, A.Schachter, J.Long, G.V.Arance, A.Grob, J.J.Mortier, L.Daud, A.Carlino, M.S.McNeil, C.Lotem, M.Larkin, J.Lorigan, P.Neyns, B.Blank, C.U.Hamid, O.Kosh, M.Zhou, H.Ibrahim, N.Ebbinghaus, S.Robert, C. (2015). Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma, Cancer Research, Vol.75 (15_Supplement), p.CT101.

Sinha, R.Larkin, J.Gore, M.E.Fearfield, L. (2015). Incidence and management of skin-related adverse events associated with vemurafenib in BRAF V600E-positive metastatic melanoma: